AU2006345724A1 - Compositions and methods for the treatment of muscle wasting - Google Patents

Description

WO 2008/005002 PCT/US2006/025657 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE WASTING BACKGROUND 5 Increase in muscle growth has been an important field both for treatment of muscle wasting conditions and for farm and food animals. The muscle wasting conditions include Duchenne muscular dystrophy (DMD), multiple types of limb girdle MD (LGMD) and other congenital MDs (CMD), sarcopenia, cancer cachexia, Diabetes mellitus. Progressive muscle damage and muscle loss, tissue inflammation and replacement of healthy muscle with fibrous 10 and fatty tissues result in disability and fatality. In animal husbandry, such as for food animals, any methods that increase the proportion and weight of muscle will greatly benefit the industry. However, there have been no effective means to treat muscle wasting conditions and to promote muscle growth in animals. 15 SUMMARY OF INVENTION In one aspect, the invention provides compositions and methods for treatment of muscle wasting conditions and/or promotion of muscle growth using compositions containing one or more oligonucleotides. In some embodiments the invention provides compositions suitable for administration to an animal containing a modified oligonucleotide containing 7 to 75 contiguous 20 ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages, where the modified oligonucleotide is complementary to a region of a gene selected from the group consisting of the 5' UTR region, translational start site, the 3' UTR, and translational termination site, and wherein the gene is related to a muscle wasting condition. In some embodiments, the modified oligonucleotide has a Tm of about 75-115 "C. at a concentration of 1 mM and a length of 10 to 26 25 bases, or a Tm of about 40 C to 85 'C at a concentration of 1 pM and a length of 10 to 26 bases. In some embodiments, the oligonucleotide comprises a nucleotide selected from the group consisting of ribonucleotides and deoxyribonucleotides. In some embodiments, the oligonucleotide contains one or more nucleotides in which the 2' position comprises a substituent, for example, hydrogen, methoxy, propoxy, methoxy-ethoxy, fluorine, chlorine, 30 bromine and iodine. In some embodiments, the modified oligonucleotide is 3' and/or 5' end modified. In some embodiments, the modified oligonucleotide is 3' and/or 5' end-blocked. In some embodiments, the oligonucleotide is an antisense oligonucleotide, e.g., an antisense oligonucleotide complementary to a myostatin gene, for example, an animal, mammalian, or human myostatin gene. In some embodiments, the oligonucleotide comprises a sequence -1- WO 2008/005002 PCT/US2006/025657 eedddfdfthegotgpe' sitting of SEQ ID NOS 1-191. In some embodiments, the oligonucleotide comprises an RNAi, ribozyme or deoxyribozyme. In some embodiments, the composition contains a plurality of modified oligonucleotides, e.g., two modified oligonucleotides. 5 In some embodiments, the invention provides a method of treating a muscle wasting condition comprising administering to an individual suffering from a muscle wasting condition an effective amount a composition of the invention. In some embodiments, the invention provides a method of promoting muscle growth in an individual comprising administering to the individual an effective amount of a composition of the invention. In some embodiments, the 10 individual is a mammal. In some embodiments, the individual is a human. In some embodiments, the oligonucleotide comprises 7 to 75 modified nucleotides containing contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages, wherein the modified oligonucleotide is complementary to a region of genes involved in muscle wasting conditions. In some embodiments, the composition contains two, three, four, five, or 15 more than five different modified oligonucleotides. In some embodiments, the modified oligonucleotide is complementary to a region of the gene selected from the group consisting of the 5' UTR region, translational start site, the 3' UTR, and translational termination site. In some embodiments, the modified oligonucleotide has a Tm of about 75-115 "C at a concentration of 1 mM and a length of 10 to 26 bases, or a Tm of about 40 "C to 85 "C at a concentration of 1 pM 20 and a length of 10 to 26 bases. The preferred compositions contain either antisense oligonucleotides or siRNA. The invention provides compositions and methods for treatment of muscle wasting conditions for human and animals. The invention also provides methods for use of compositions in food dietary supplement. The present invention provides compositions and methods for the modulation of expression of genes that code for gene products that are involved 25 in muscle wasting and/or muscle growth conditions. In one aspect, the invention provides compositions. In some embodiments, the invention provides a composition suitable for administration to an animal comprising a modified oligonucleotide containing contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages, wherein the modified oligonucleotide is complementary to a region of a 30 gene coding for myostatin or a myostatin receptor. In some embodiments, the composition contains two, three, four, five, or more than five different modified oligonucleotides. In some embodiments, the oligonucleotide comprises about seven to seventy-five nucleotides containing seven or more contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages. In some embodiments, the modified oligonucleotide is complementary to a region of 35 the gene selected from the group consisting of the 5' UTR region, translational start site, the 3' -2- WO 2008/005002 PCT/US2006/025657 UU;nttamlatiifertdffination site. In some embodiments, the modified oligonucleotide has a Tm of about 75-115 *C at a concentration of 1 mM and a length of 10 to 26 bases, or a Tm of about 40 *C to 85 *C at a concentration of 1 pM and a length of 10 to 26 bases. In some embodiments, the ribose group of the oligonucleotide has a modified 2' substituent; in some 5 embodiments the modified substituent is selected from the group consisting of hydrogen, methoxy, propoxy, methoxy-ethoxy, fluorine, chlorine, bromine and iodine. In some embodiments, the modified oligonucleotide is 3' end-blocked. In some embodiments, the modified oligonucleotide is 5' end-blocked. The invention also provides a pharmaceutical composition comprising a composition 10 suitable for administration to an animal comprising a modified oligonucleotide containing contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages, wherein the modified oligonucleotide is complementary to a region of a gene coding for myostatin or a myostatin receptor, and a pharmaceutically acceptable excipient. In some embodiments, the invention provides an antisense oligonucleotide that inhibits 15 the expression of myostatin or myostatin receptor genes, wherein the oligonucleotide is selected from the group consisting of SEQ ID NOS: 1 - 191. In other embodiments, the invention provides a composition comprising an interfering RNA (RNAi) that modulates expression of myostatin or a myostatin receptor. In some embodiments, the RNAi composition comprises double-stranded RNA of 21 -25 nucleotides 20 with overhangs of 2 nucleotides at both 3' ends. 30 - 52% of the G+C content of the double stranded region, A/U base-pairing in positions 15 -19 in sense strand, and no internal repeats. In yet other embodiments, the invention provides a composition comprising a DNAzyme, wherein the DNAzyme modulates expression of myostatin or a myostatin receptor. In some embodiments, the DNAzyme comprises a catalytic domain that comprises the nucleotide 25 sequence GGCTAGCTACAACGA and specifically cleaves mRNA coding for myostatin or a myostatin receptor at any purine:pyrimidine site to which the catalytic domain is directed, a first binding domain contiguous with the 5'end of the catalytic domain, and a second binding domain contiguous with the 3'end of the catalytic domain, wherein each binding domain hybridizes with a region immediately flanking the cleavage site. 30 In'still other embodiments, the invention provides a composition for the modulation of expression of myostatin or myostatin receptors comprising two or more gene-modulating oligonucleotides, wherein at least one oligonucleotide is targeted to myostatin, and at least one oligonucleotide is targeted to a gene that is not myostatin. In some embodiments the composition contains gene-modulating oligonucleotides that comprise one or more 35 oligonucleotides selected from the group consisting of antisense oligonucleotides, RNAi, and -3- WO 2008/005002 PCT/US2006/025657 DNA,2Y-fflM:hir setb Iin otliments the composition contains antisense oligonucleotides. In some embodiments the non-myostatin gene is a gene coding for a protein selected from the group consisting of Activin A Receptor IIB, Tolloid metalloproteinase, NF-kappaB, TNF-alpha, MuRF1, Caspase-3, Atrogin-1, RAS, P38 MAPK, MKK 3, MKK 6, JNK, c-myc, c-jun, ASK-1, 5 TAK-1, smad, cyclin dependent kinase inhibitor p21, Gadd45, IL-6, and PIF (Table 1 and Table 2). In some embodiments the composition contains one or more antisense oligonucleotides targeted to myostatin is selected from the oligonucleotides shown in Tables 3, 4, and 5 and one or more antisense oligonucleotides targeted to a non-myostatin gene is selected from the oligonucleotides shown in Table 3 and Table 4. 10 In another aspect, the invention provides methods. In one embodiment, the invention provides a method of modulating expression of myostatin in a cell containing a myostatin-encoding polynucleotide comprising contacting the cell with an oligonucleotide that modulates the expression of said myostatin-encoding polynucleotide, wherein the oligonucleotide is an antisense oligonucleotide comprising contiguous ribose groups linked by achiral 5' to 3' 15 internucleoside phosphate linkages. In other embodiments, the invention provides a method of modulating expression of inyostatin in a cell containing a myostatin-encoding polynucleotide comprising contacting the cell with an oligonucleotide that modulates the expression of said myostatin-encoding polynucleotide, wherein the oligonucleotide is selected from the group consisting of RNAi, ribozymes, and 20 DNAzymes. In other embodiments, the invention provides a method of modulating expression of myostatin in a cell containing a myostatin-encoding polynucleotide and a non-myostatin encoding polynucleotide comprising contacting the cell with a first gene-modulating oligonucleotide and a second gene-modulating oligonucleotide, wherein the first oligonucleotide 25 modulates the expression of said myostatin-encoding polynucleotide and the second oligonucleotide modulates the expression of a polynucleotide selected from the group consisting of said myostatin-encoding polynucleotide and said non-myostatin-encoding polynucleotide. In some of these embodiments, the oligonucleotides are selected from the group consisting of antisense oligonucleotides, RNAi, ribozymes, and DNAzymes. In some embodiments, the 30 oligonucleotides comprise a first antisense oligonucleotide and a second antisense oligonucleotide In another embodiment, the invention provides a method of modulating expression of myostatin in an animal comprising administering to the animal an oligonucleotide that modulates the expression of a myostatin-encoding polynucleotide, wherein the oligonucleotide is -4- WO 2008/005002 PCT/US2006/025657 -annitrstefeiW'tta Riosd bfT.61 to 100 mg/kg. In some of these embodiments, the animal is a food animal and the administration results in increased muscle mass. In another embodiment, the invention provides a method of modulating expression of myostatin in an animal comprising administering to the animal an oligonucleotide that modulates 5 the expression of a myostatin-encoding polynucleotide, wherein the oligonucleotide is an antisense oligonucleotide comprising contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages. In some of these embodiments, the animal is a food animal and the administration results in increased muscle mass. In yet another embodiment, the invention provides a method of modulating expression of 10 myostatin in an animal comprising administering to the animal an oligonucleotide that modulates the expression of a myostatin-encoding polynucleotide, wherein the oligonucleotide is selected from the group consisting of RNAi, ribozymes, and DNAzymes. In some of these embodiments, the animal is a food animal and the administration results in increased muscle mass. In still yet another embodiment, the invention provides a method of modulating 15 expression of myostatin in an animal comprising administering to the animal a first gene modulating oligonucleotide and a second gene-modulating oligonucleotide, wherein the first oligonucleotide modulates the expression of a myostatin-encoding polynucleotide and the second oligonucleotide modulates the expression of a polynucleotide selected from the group consisting of a myostatin-encoding polynucleotide and a non-myostatin-encoding polynucleotide. In some 20 of these embodiments, the animal is a food animal and the administration results in increased muscle mass. In another embodiment, the invention provides a method of treating an animal suffering from a muscle-wasting condition comprising administering to the animal an oligonucleotide that modulates the expression of a myostatin-encoding polynucleotide, wherein the oligonucleotide is 25 administered at a dose of 0.001 to 100 mg/kg. In another embodiment, the invention provides a method of treating an animal suffering from a muscle-wasting condition comprising administering to the animal an oligonucleotide that modulates the expression of a myostatin-encoding polynucleotide, wherein the oligonucleotide is an antisense oligonucleotide comprising contiguous ribose groups linked by achiral 5' to 3' 30 internucleoside phosphate linkages. In still another embodiment, the invention provides a method of treating an animal suffering from a muscle-wasting condition comprising administering to the animal an oligonucleotide that modulates the expression of a myostatin-encoding polynucleotide, wherein the oligonucleotide is selected from the group consisting of RNAi, ribozymes, and DNAzymes -5- WO 2008/005002 PCT/US2006/025657 "Te'elmoiT also"provides a method of treating an animal suffering from a muscle wasting condition comprising administering to the animal a first gene-modulating oligonucleotide and a second gene-modulating oligonucleotide, wherein the first oligonucleotide modulates the expression of a myostatin-encoding polynucleotide and the second oligonucleotide 5 modulates the expression of a polynucleotide selected from the group consisting of a myostatin encoding polynucleotide and a non-myostatin-encoding polynucleotide. In some embodiments, the oligonucleotides are selected from the group consisting of antisense oligonucleotides, RNAi, ribozymes, and DNAzymes. In a further aspect, the invention provides kits that contain one or more of the compositions of 10 the invention and, optionally, instructions for the use of the compositions. INCORPORATION BY REFERENCE All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent 15 application was specifically and individually indicated to be incorporated by reference. BRIEF DESCRIPTION OF THE DRAWINGS The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained 20 by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which: Figure 1 is a bar graph representing muscle weight in three groups of mice treated with saline, mock, or RNA antisense oligonucleotides. 25 Figure 2 depicts the effect of RNA oligos targeted to Foxol on expression of MyoD and GDF-8 in normal mice. A, Western blots were performed on the effect of RNA oligo on protein expression level of MyoD (C) and GDF-8 (B) in normal mice. Quantitative RT-PCR analysis was done on the effect of RNA oligo on miRNA expression level of Foxol (D), GDF-8 (E) and MyoD (F) in normal mice. Data are mean SD (n=6), P<0.01*. 30 Figure 3 depicts the effect of RNA oligos targeted to Foxol (GRR-7) and control on mass of muscles in S-180 tumor mice. Dissected muscle mass at the end of the study (n=6), P<0.01 *. Figure 4 depicts the effect of RNA oligos targeted to Foxol on expression of MyoD and GDF-8 in S180 mice. A, Western blots were performed on the effect of RNA oligo on protein 35 expression level of GDF-8 (B) and MyoD (C) in S180 mice. Quantitative RT-PCR analysis was -6- WO 2008/005002 PCT/US2006/025657 aofid.6i1the618ffscTofRN oligo on mRNA expression level of Foxo1 (D), GDF-8 (E) and MyoD (F) in normal mice. Data are mean ± SD (n=6), P<0.01**. Figure 5 depicts the effect of RNA oligos targeted to myostatin on muscle mass in S-180 implanted mice: (A) Dissected muscle mass at the end of the study. Results showed that muscle 5 mass was increased by 26% in mixed RNA oligos compared to control group (n=6, mean ± SD, p<0.05).5 (B) The ratio of muscle leg's mass to body. The results indicated that mixed RNA oligos targeted to myostatin could increase muscle mass in S-180 tumor mice (mean ± SD, p<0.05). 5 (C and D) Quantitative RT-PCR analysis of myostatin and MyoD expression at mRNA level in mouse model after injecting RNA oligos 2 weeks (P<0.01). 10 DETAILED DESCRIPTION OF THE INVENTION The present invention provides compositions and methods for the modulation of expression of genes that code for gene products that are involved in muscle wasting and/or muscle growth conditions. Accordingly, the invention provides compositions and methods using 15 the compositions, for enhancement of muscle growth and treatment of diseases associated with inadequate muscle growth, abnormal fat accumulation, or muscle wasting. The invention also provides compositions and methods using the compositions, for enhancing normal muscle growth where such enhancement is desired (e.g., in farm animals). Generally, the compositions and methods of the invention utilize oligonucleotides that 20 modulate gene expression, also referred to herein as "gene modulators" and "gene-modulating oligonucleotides." Exemplary gene modulators of the invention include antisense oligonucleotides, interfering RNA (RNAi), ribozymes, and DNAzymes. In some embodiments, the invention provides a single gene modulator targeted at a single gene involved in muscle growth and maintenance, e.g., myostatin. In other embodiments, the invention provides 25 combinations of gene modulators. These combinations include: combinations of different types of gene modulators, combinations of gene modulators targeted to different parts of the same gene, and combinations of gene modulators targeted to different genes, as well as combinations of any of the aforementioned combinations. The invention further provides modified oligonucleotides for use in any of the above 30 compositions. In some preferred embodiments, oligonucleotides used in the invention can be, e.g., end-blocked, protonated, exhibit substantial acid resistance, substantial nuclease resistance, and/or contain achiral intemucleoside phosphate linkages and modified ribose or deoxyribose substituents. -7- WO 2008/005002 PCT/US2006/025657 fiweiVbntioTrffiftthd provides methods using the compositions of the invention. Methods include methods of treating animals (e.g. mammals, humans) by modulating gene expression in cells by contacting cells with compositions of the invention. Methods also include methods of treatment of disorders using the gene modulating compositions of the invention. 5 Disorders for treatment include muscle wasting disorders or disorders associated with decreased muscle mass and/or increased obesity. As used herein, the term "muscle wasting disorder," used synonymously herein with the term "muscle wasting condition," encompasses disorders or conditions in which muscle wasting is one of the primary symptoms, such as muscular dystrophy, spinal cord injury, neurodegenerative diseases, anorexia, sarcopenia, cachexia, 10 muscular atrophy due to immobilization, prolonged bed rest, or weightlessness, and the like, as well as disorders in which an abnormally high fat-to-muscle ratio is implicated in a disease or pre-disease state, e.g., Type II diabetes or Syndrome X. In addition, the invention provides methods of increasing muscle mass in animals where such an increase is desirable, e.g., in food animals such as mammals and fish. 15 In addition, the invention provides kits that provide compositions of the invention, optionally including instructions for use of the compositions in methods of the invention. The gene modulators of the invention include antisense oligonucleotides, interfering RNA (RNAi), ribozymes, and DNAzymes. Compositions of the invention contain one or more gene modulators that is/are targeted to one or more areas of one or more genes. A composition 20 containing a nucleic acid "modulates" or is "capable of modulating" or is a "modulator" of gene expression if the nucleic acid modulates gene expression or if the nucleic acid encodes a gene product that modulates gene expression. As used herein, the term "modulate" includes both inhibition and stimulation, as well as other changes (e.g., production of a modified gene product) in gene expression. The term "inhibition" is intended to include both complete and partial 25 inhibition of expression. In various embodiments, gene expression is inhibited to a level of about 1-99%, or at least about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% lower than the wild type level of gene expression. In some embodiments, expression is inhibited to a level at least about 1-99%, or at least aboutl, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% lower than the wild type level of gene 30 expression. Genes may be chosen for modulation based on their involvement in one or more pathways that are altered in the disorder to be treated. In some embodiments, the invention provides compositions that contain a gene modulator targeted to one area of one gene, e.g., myostatin. In some embodiments, the invention provides gene modulators that are targeted to 35 more than one area of one gene, e.g., myostatin. In some embodiments, the invention provides -8- WO 2008/005002 PCT/US2006/025657 gene'rodnfators thatlai targeted to multiple genes, e.g., myostatin and myostatin receptor genes, as well as other genes described herein (Table 1 and Table 2). In these embodiments, more than one area of a gene may be targeted 5 I. Compositions of the invention The compositions of the invention include one or more agents capable of modulating expression of a gene or genes associated with muscle wasting and/or muscle growth, and the conditions associated with them. Typically, the gene modulators of the invention are inhibitory to gene expression and include, without limitation, antisense oligonucleotides, interfering RNA 10 (RNAi), ribozymes, and DNAzymes. Compositions of the invention contain one or more gene modulators that is/are targeted to one or more areas of one or more genes. In some embodiments, the invention provides compositions that contain a gene modulator targeted to one area of one gene, e.g., myostatin. In some embodiments, the invention provides gene modulators that are targeted to more than one area of one gene, e.g., myostatin. In some embodiments, the 15 invention provides gene modulators that are targeted to multiple genes, e.g., myostatin, myostatin receptor genes, and/or myostatin transcription factors. In these embodiments, more than one area of a gene may be targeted. In preferred embodiments, the invention provides compositions that contain combinations of gene modulators for enhancement of muscle growth and treatment of diseases 20 associated with inadequate muscle growth or muscle wasting, or for enhancing normal muscle growth (e.g., in farm animals). These combinations include: combinations of different types of gene modulators, combinations of gene modulators targeted to different parts of the same gene, and combinations of gene modulators targeted to different genes, as well as combinations of any of the aforementioned combinations. 25 The invention further provides modified oligonucleotides for use in any of the above combinations. In embodiments, oligonucleotides used in the invention can be, e.g., end-blocked, protonated, exhibit substantial acid resistance, substantial nuclease resistance, and/or contain achiral internucleoside phosphate linkages and modified ribose or deoxyribose substituents. The compositions and methods of the invention may be applied to any gene for which it 30 is desired to alter expression in order to provide a therapeutic effect in muscle wasting disorders, or to produce a desired increase in muscle mass. In general, the major targets are genes involved in muscle growth and maintenance; however, in the majority of cases, several pathways involving multiple genes are affected by a given disorder, and the invention provides not only compositions and methods targeted to single genes (e.g., myostatin) but also compositions and 35 methods targeted to multiple genes, or to multiple areas on a single gene, or both. -9- WO 2008/005002 PCT/US2006/025657 A. Expression-modulating compositions Any type of nucleic acid-based therapeutics that modulates expression of a gene may be used in the compositions and methods of the invention. These include antisense 5 oligonucleotides, ribozymes, interfering RNA (RNAi), and DNAzymes. Each of these approaches has one central theme in common, that is, the recognition of their target DNA or mRNA sequences via Watson-Crick base-pairing. The present invention thus relates to polynucleotides that hybridize to any of the gene sequences described herein, preferably under stringent conditions. A stringent condition refers to a condition that allows nucleic acid duplexes 10 to be distinguished based on their degree of mismatch. Such polynucleotides (e.g., antisense and RNAi) can be used to inhibit the expression of muscle wasting-associated gene product. Such polynucleotides can also serve as probes and primers for research and diagnostic purposes. The term "oligonucleotides" as used herein, refers to a molecule comprising nucleotides (i.e., ribonucleotides, deoxyribonucleotides, or both). The term includes monomers and polymers 15 of ribonucleotides and deoxyribonucleotides, or mixtures thereof, with the nucleotides being connected together via, for example 5' to 3' linkages, 5' to 2' linkages, etc. The nucleotides used in the oligonucleotides may be naturally occurring or may be synthetically produced analogues that are capable of forming base-pair relationships with naturally occurring base pairs. Examples of non-naturally occurring bases that are capable of forming base-pairing relationships include, 20 but are not limited to, aza and deaza pyrimidine analogues, aza and deaza purine analogues, and other heterocyclic base analogues, wherein one or more of the carbon and nitrogen atoms of the purine and pyrimidine rings have been substituted by heteroatoms, e.g., oxygen, sulfur, selenium, phosphorus, etc. 25 1. Antisense oligonucleotides Antisense oligonucleotides contain short, chemically synthesized DNA or RNA oligonucleotides with base-pair homology against the mRNA target of interest. Without wishing to be limited by theory, it is generally believed that antisense oligonucleotides act to inhibit gene expression by blocking translation of mRNA or by targeting the RNA for degradation by RNase 30 H. Antisense oligonucleotides can block splicing, translation, or nuclear-cytoplasmic transport. The mechanisms of action of antisense oligonucleotides vary depending on the backbone of the oligonucleotide. Antisense oligonucleotides can be complementary to an entire coding region or only to a portion thereof. An antisense oligonucleotide herein can be, for example, about 5, 10, 15, 20, 25, 30, 35, 35 40, 45, 50, 60, 70, 80, 90, 100, or more than 100 nucleotides in length. Preferably, the -10- WO 2008/005002 PCT/US2006/025657 01fgd1tudm614M 1&abbtit tiWrV to about 75 nucleotides in length. The oligonucleotide can also be about eight to about 40, or at about 10 to about 30, or about 15 to about 30 sequential nucleotides. In one embodiment, the oligonucleotide is about 12 to about 26 nucleotides in length. 5 Typically, the procedure for making an antisense oligonucleotide composition includes: (i) selecting an oligonucleotide that is adjacent to or overlaps a target region of a gene, (ii) determining the Gibbs Free energy value associated with the oligonucleotide in reference to the target gene, (iii) assessing Tm in reference to the target gene, and (iv) performing a sequence database search to determine the oligonucleotide overlaps the 5' UTR, the translational start 10 sequence, the 3' UTR, or the translational termination site of an mRNA of a gene different from the target gene. Accordingly, in some embodiments, the antisense oligonucleotides of the present invention can be directed to a translational start site, a 5' UTR, a 3' UTR, or a termination site. Preferably, the oligonucleotide is adjacent to or overlaps the translational start site of the gene by at least about one base. Still preferred, the oligonucleotide overlaps the translational start site by 15 at least about two bases. Still more preferred, the oligonucleotide overlaps the translational start site by at least about three bases. It is generally preferable to design an RNA or DNA that has the same or similar base sequence as the portion of the complement of a gene that encodes the 5' end of an RNA. However, a nucleic acid may also have, for example, a same or similar base sequence as other 20 regions of the gene, such as the region encoding a translation start site or the 3' untranslated region. In another example, a nucleic acid may be designed to reflect the region around a splice donor or splice acceptor site, either with or without the intervening intron. Of particular interest are nucleic acid molecules whose sequences comprise all or a fragment of the sequence of the complement of a gene that is over-expressed in individuals exhibiting the disease or condition. 25 The identification of overexpression of a gene can be through molecular means, e.g., detection of expression in affected tissue using conventional molecular techniques (e.g., Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press). Overexpression of a gene may also be detected using array technology, or inferred from the results of protein assays, such as ELISA. 30 Suitable antisense oligonucleotides for the present invention can be determined by evaluating the Delta G or Gibbs Free energy of oligonucleotide binding to the complementary RNA strand at 37 "C. and the Tm. The Gibbs Free energy and Tm are measured from the part of the target gene that corresponds to the RNA oligonucleotide that is added. These values can be calculated using, e.g., the program found on ftp://rna.chem.rochester.edu and are described in -11- WO 2008/005002 PCT/US2006/025657 M61. Biol. 288, 911-940 and Matthews et al. (1999) RNA 5, 1458 1469. Accordingly, some preferred embodiments of the invention provides a composition comprising an oligonucleotide, (i) wherein said oligonucleotide is about 10 to about 30 5 nucleotides in length, (ii) the Gibbs Free energy of the binding of said oligonucleotide/RNA target duplex at 37 "C. is -15 kCal, (iii) said oligonucleotide is complementary to a region within the target gene selected from the group consisting of 5' UTR, translational start site and translational termination site. The Gibbs free energy is measured between that part of the target gene that corresponds 10 to the oligonucleotide, that part typically being the 5'UTR, translational start site or the translational termination site. In a preferred embodiment, the Gibbs Free energy of the binding of said oligonucleotide/RNA target duplex at 37 "C is -20 kCal. Also preferred, the Gibbs Free energy is -25 kCal. For 12-14 mer oligonucleotides, the Gibbs Free energy is preferably 15 kCal, for 15-17 mer oligonucleotides, the Gibbs Free energy is preferably -20 kCal, for 18-20 15 mer oligonucleotides, the Gibbs Free energy is preferably -25 kCal, for 21-23 mer oligonucleotides, the Gibbs Free energy is -30 kCal, and for 24-26 mer oligonucleotides, the Gibbs Free energy is :;35 kCal. Further provided by the present invention is a composition comprising an oligonucleotide, (i) wherein said oligonucleotide is about 10 to about 30 nucleotides in length, 20 (ii) the Tm of said oligonucleotide to a target gene is about 65-90 "C.., (iii) said oligonucleotide is complementary to a region within the target gene selected from the group consisting of 5' UTR, translational start site an termination site. Preferably, the oligonucleotide has a Tm of about 75-90 "C.. Still preferred, the oligonucleotide has a Tm of about 85-90 "C. Still preferred, the Tm of said oligonucleotide to a target gene at 1M monovalent cation concentration is about 65-90 "C. The 25 Gibbs free energy is measured between that part of the target gene that corresponds to the oligonucleotide, that part typically being the 5' UTR, 3 'UTR, translational start site or the translational termination site. The oligonucleotide sequence can be derived from any of the genes listed in Tables 1 and 2, or any other gene the modulation of whose expression is likely to produce a desirable 30 therapeutic result in a muscle-wasting-associated condition. Table 3, 4 and 5 show representative antisense sequences that may be used in embodiments of the invention; these sequences are merely representative, and any sequence that acts as an antisense oligonucleotide and that modulates expression of a gene involved in a muscle-wasting condition may be used in compositions and methods of the invention. -12- WO 2008/005002 PCT/US2006/025657 Msomid MAWbifts, one or more of the antisense oligonucleotides of the invention is a modified oligonucleotide. Linkage and backbone modifications have shown a great promise for oligonucleotides to be used in vivo, such as 2'-O-methyls, 2'-O-allyls, locked nucleic acids and peptide nucleic acids. 5 In a preferred embodiment, the antisense oligonucleotides of the invention are modified to provide increased acid resistance as compared to unmodified oligonucleotide, or to provide increased resistance to endonuclease, or both. Further modifications are described below. An antisense oligonucleotide can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. Alternatively, the antisense nucleic acid 10 can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest). Although the specific antisense sequences described herein (e.g., in Tables 3, 4 and 5) depict the sequences as oligonucleotides containing only deoxyribonucleotide residues, it is to be 15 understood that the present invention also includes embodiments wherein the oligonucleotides are composed of ribonucleotide residues (e.g., by substituting uridine for thymidine, and ribosyl substituents for deoxyribosyl substituents). Moreover, it is to be understood that the present invention also includes the embodiments in which the oligonucleotides are composed of only deoxyribonucleotide residues, of only ribonucleotide residues, or of mixtures of 20 deoxyribonucleotide and ribonucleotide residues. In some embodiments, antisense oligonucleotides of the present invention display greater than or equal to 60, 70, 80, 90, 95, or 99 percent sequence identity to-a nucleotide sequence selected from the group of SEQ ID NO: 1 - 191. The degree of similarity between two sequences can be determined using methods well 25 known to the art (e.g., computer programs including Fasta (Oxford Molecular Group Inc.) and BLAST (www.ncbi.nlm.nih.gov) (Altschul et al. (1997) Nucleic Acid Res. 25, 3389-3402). These methods can be employed to take into account gaps in the sequences due to deletions or insertions. Homology or sequence identity at the nucleotide or amino acid sequence level determined by BLAST (Basic Local Alignment Search Tool) analysis uses the algorithm 30 employed by the programs blastp, blastn, blastx, tblastn and tblastx (Altschul et al. (1997) Nucleic Acids Res. 25, 3389-3402 and Karlin et al. (1990) Proc. Natl. Acad. Sci. USA 87, 2264 2268, both fully incorporated by reference) which are tailored for sequence similarity searching. The approach used by the BLAST program is to first consider similar segments, with gaps (non contiguous) and without gaps (contiguous), between a query sequence and a database sequence, -13- WO 2008/005002 PCT/US2006/025657 thbn!I hat6 the-'tatistidA1 significance of all matches that are identified and finally to summarize only those matches which satisfy a preselected threshold of significance. In some embodiments the antisense oligonucleotides of the invention have a Guanine:Cytosine (GC content) greater than 35 percent. The GC content is preferably greater 5 than 40 percent and most preferably, greater than 45 percent. 2. Ribozymes "Ribozyme" refers to a nucleic acid molecule which is capable of cleaving a specific nucleic acid sequence. Ribozymes may be composed of RNA, DNA, nucleic acid analogues 10 (e.g., phosphorothioates), or any combination of these (e.g., DNA/RNA chimerics). In some embodiments, a ribozyme refers to RNA molecules that contain anti-sense sequences for specific recognition, and an RNA-cleaving enzymatic activity. As noted above, the present invention provides ribozymes having the ability to cleave or otherwise inhibit nucleic acid molecules which are either directly, or indirectly (e.g., they encode 15 proteins) involved in muscle wasting disorders. Several different types of ribozymes may be constructed for use within the present invention, including for example, hammerhead ribozymes (Rossi, J. J. et al., Pharmac. Ther. 50:245-254, 1991) (Forster and Symons, Cell 48:211-220, 1987; Haseloff and Gerlach, Nature 328:596-600, 1988; Walbot and Bruening, Nature 334:196, 1988; Haseloff and Gerlach, Nature 334:585, 1988; Haseloff et al., U.S. Pat. No. 5,254,678), 20 hairpin ribozymes (Hampel et al., Nucl. Acids Res. 18:299-304, 1990, and U.S. Pat. No. 5,254,678), hepatitis delta virus ribozymes (Perrotta and Been, Biochem. 31:16, 1992), Group I intron ribozymes (Cech et al., U.S. Pat. No. 4,987,071) and RNase P ribozymes (Takada et al., Cell 35:849, 1983); (see also, WO 95/29241, entitled "Ribozymes with Product Ejection by Strand Displacement"; and WO 95/31551, entitled "Novel Enzymatic RNA Molecules." 25 The sequence requirement at the cleavage site for the hammerhead ribozyme is any RNA sequence consisting of NUlH (where N is any of G, U, C, or A and H represents C, U, or A) can be targeted. Accordingly, the same target within the hairpin leader sequence, GUC, is useful for the hammerhead ribozyme. The additional nucleotides of the hammerhead ribozyme or hairpin ribozyme is determined by the target flanking nucleotides and the hammerhead consensus 30 sequence (see Ruffner et al., Biochemistry 29:10695-10702, 1990). Ribozymes, as well as DNA encoding such ribozymes and other suitable nucleic acid molecules, can be chemically synthesized using methods well known in the art for the synthesis of nucleic acid molecules (see e.g., Heidenreich et al., J FASEB 70(1):90-6, 1993; Sproat, Curr. Opin. Biotechnol. 4(1):20-28, 1993). Alternatively, commercial suppliers such as Promega, -14- WO 2008/005002 PCT/US2006/025657 [viadson8frWtis,, s6A;,pryc1e a series of protocols suitable for the production of nucleic acid molecules such as ribozymes. During synthesis, the ribozyme can be modified by ligation to a DNA molecule having the ability to stabilize the ribozyme and make it resistant to RNase (Rossi et al., Pharmac. Ther. 5 50:245-254, 1991). In another embodiment, the ribozyme can be modified to a phosphothio analog for use in liposome delivery systems. This modification also renders the ribozyme resistant to endonuclease activity. In yet another embodiment, the ribozyme can be modified to contain propanediol linkages or to incorporate 2'-0-methylated nucleotides. Any ribozyme that modulates expression of a gene involved in muscle wasting 10 conditions, or that promotes muscle growth where muscle growth is desirable, e.g., the genes of Tables 1 and 2, may be used in the compositions and methods of the invention. 3. Interfering RNA (RNAi) In another embodiment of the present invention, double stranded nucleic acids can be 15 used to inhibit expression of genes associated with muscle wasting (e.g., myostatin and myostatin receptor genes) by RNA interference. RNA interference ("RNAi") is a mechanism of post-transcriptional gene silencing in which double-stranded RNA (dsRNA) corresponding to a gene (or coding region) of interest is introduced into a cell or an organism, resulting in degradation of the corresponding mRNA. The RNAi effect persists for multiple cell divisions 20 before gene expression is regained. RNAi is therefore an extremely powerful method for making targeted knockouts or "knockdowns" at the RNA level. RNAi has proven successful in human cells, including human embryonic kidney and HeLa cells. See, e.g., Elbashir et al. Nature May 24, 2001;411(6836):494-8); Tuschl et al. (1999), Genes and Development 13:3191-3197; Zamore (2000), Cell 101:25-33, and U.S. Patent No. 6,506,559, all of which are incorporated 25 herein by reference in their entirety. Thus, the invention further provides RNAi's that inhibit expression of genes involved in muscle wasting disease. In this connection, the invention provides an RNAi that modulates expression of myostatin or a myostatin receptor. As an example, this aspect of the invention provides small (less than about 50, or less than about 40, or less than about 30 or less than about 30 20 nt) dsRNA that specifically inhibits gene expression of genes involved in muscle wasting or in limiting muscle growth (reviewed in Caplen (2002) Trends in Biotechnology 20:49-5 1). In some embodiments, the RNAi includes: (a) double-stranded RNA of 21 -25 nucleotides with overhangs of 2 nucleotides at both 3' ends; (b) 30 - 52% of the G+C content of the double stranded region; and (c) A/U base-pairing in positions 15 -19 in sense strand; and (d) no internal 35 repeats. -15- WO 2008/005002 PCT/US2006/025657 3. DNAzymes Like RNAi, DNAzyme technology also represents an ideal choice for gene suppression. Such catalytic DNA molecules offer several advantages over ribozymes and are easier to 5 synthesize at relatively low cost. Moreover, DNAzymes have a moderate-throughput capacity and act in a sequence-specific manner. This capacity for highly flexible binding and discrimination of nucleic acid substrates by virtue of Watson-Crick interactions enable DNAzymes to facilitate gene-type specific reactions for gene function validation with very high precision. See, e.g., Sun, L.Q., Cairns, M.J., Saravolac, E.G., Baker, A. and Gerlach, W.L. 10 (2000) Pharmacol. Rev. 52(3), 325 - 347; and U.S. Patent Nos. 6,617,438, 6,326,174, which are incorporated herein by reference in their entirety. Thus, this aspect of the invention provides DNAzymes that inhibit expression of genes involved in muscle wasting disease. In some embodiments, the invention provides a DNAzyme that modulates expression of myostatin or a myostatin receptor. In some embodiments, the 15 invention includes a DNAzyme that contains: (a) a catalytic domain that comprises the nucleotide sequence GGCTAGCTACAACGA (SEQ ID NO. 1) and that specifically cleaves mRNA coding for myostatin or a myostatin receptor at any purine:pyrimidine site to which the catalytic domain is directed, (b) a first binding domain contiguous with the 5'end of the catalytic domain, and (c) a second binding domain contiguous with the 3'end of the catalytic domain, 20 where each binding domain hybridizes with a region immediately flanking the cleavage site. In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to myostatin and at least one antisense oligonucleotide targeted to a myostatin receptor, e.g., ARIb. In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to human myostatin and 25 at least one antisense oligonucleotide targeted to a human myostatin receptor, e.g., ARIIb. In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to human myostatin wherein the sequence of the oligonucleotide is selected from SEQ ID NOs 1-191 and at least one antisense oligonucleotide targeted to a myostatin receptor, e.g., ARIIb. 30 In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to myostatin and at least one antisense oligonucleotide targeted to a gene product that converts inactive myostatin to an active form, e.g., TLL2. In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to human myostatin and at least one antisense oligonucleotide targeted 35 to a human gene product that converts inactive myostatin to an active form, e.g., TLL2. In some -16- WO 2008/005002 PCT/US2006/025657 Cmbdifbhm,,th6i i provides a composition that includes at least one antisense oligonucleotide targeted to human myostatin wherein the sequence of the oligonucleotide is selected from SEQ ID NOs 1-191 and at least one antisense oligonucleotide targeted to a gene product that converts inactive myostatin to an active form, human TLL2. 5 Any of these combinations may include a plurality of antisense oligonucleotides targeted to one or more of the target genes, e.g., combinations of oligonucleotides targeted to the 5' UTR, the 3'UTR, the start signal, coding sequences, and/or the termination signal, of one or more of the target genes. 10 B. Modifications of nucleic acids The oligonucleotides that are employed in accordance with the present invention may be modified. An oligonucleotide that comprises at least one modification has one or more chemical modifications at the molecular level of the natural molecular structures of all or any of the 15 nucleic acid bases, sugar moieties, internucleoside phosphate linkages, as well as molecules having added substituents, such as diamines, cholesteryl or other lipophilic groups, or a combination of modifications at these sites. For example, oligonucleotides can be end-blocked, protonated, exhibit substantial acid resistance, substantial nuclease resistance, and contain achiral internucleoside phosphate linkages and modified ribose or deoxyribose substituents. 20 The term "end-blocked" as used herein refers to a nucleic acid with a chemical modification at the molecular level that prevents the degradation of selected nucleotides, e.g., by exonuclease action. This chemical modification is positioned such that it protects the integral portion of the nucleic acid, for example the portion of an RNA or DNA that is chemically similar to the gene involved in the physiological condition. An end block may be a 3' end block, a 5' end 25 block, or both. For example, a 3' end block may be at the 3'-most position of the molecule, or it may be internal to the 3' ends, provided it is 3' of the integral sequences of the nucleic acid. The term "protonated compound" refers to a molecule of the invention that, when dissolved in water having a pH of 7 causes the pH of the solution to fall. Generally, compounds are protonated by adding protons to the reactive sites on the molecule, although other 30 modifications of the molecule are possible, and are intended to be encompassed by this term. Such protonation can be accomplished, for example by incubating the compound in the presence of a strong acid, most preferably one with a volatile conjugate base. The term "protonation" and "acidification" as used interchangeably herein refers to the process by which protons (or positively charged hydrogen ions) are added to proton acceptor sites on a compound of the 35 invention. The proton acceptor sites include the substituted or unsubstituted phosphates of the -17- WO 2008/005002 PCT/US2006/025657 "cenltyddy,-agweinstr$ additional proton acceptor sites on either the central group or the end blocking groups. As the pH of the solution is decreased, the number of these acceptor sites which are protonated increases, resulting in a more highly protonated compound. Many nucleic acid backbones are not stable at low pH (e.g., pH 1-3) and experience 5 depurination, although a number of backbones are relatively stable at pH 4-5. One aspect of the present invention reflects the recognition that certain modifications, including 2'-halide, 2'-0 alkyl, 3'-O-alkyl, and 2'-O-alkyl-n(O-alkyl) nucleic acid molecules are stable at the desired pH of 2 to 1. These modifications enhance the ability of the oligonucleotides of the pharmacological compositions of the present invention to affect a condition in vivo. Thus, the composition of the 10 present invention may include nucleic acid molecules that are substantially acid resistant. The compositions of the present invention may also include nucleic acid molecules that are nuclease resistant. This includes nucleic acid molecules completely derivatized by 2'-0 methylphosphodiesters, 2'-O-alkyl, 2'-O-alkyl-n(O-alkyl), 2'-fluoro, 2'-deoxy erythropentofuranosyl, chimeric linkages, and any other backbone modifications, as well as other 15 modifications, which render the nucleic acid molecules substantially resistant to endogenous nuclease activity. Additional suitable methods of rendering nucleic acid molecules nuclease resistant include, but are not limited to, covalently modifying the purine or pyrimidine bases that comprise the nucleic acid. For example, bases may be methylated, hydroxymethylated, or otherwise substituted (e.g., glycosylated) such that the nucleic acid molecules comprising the 20 modified bases are rendered substantially nuclease resistant. Nuclease resistance also aids the oligonucleotides of the compositions of the present invention in retaining their effect in vivo. Preferably, the oligonucleotides of the of the present invention remain relatively unchanged chemically upon administration to a subject and retain their activity in acidic conditions (pH less than 6.0) or in the presence of an endonuclease or exonuclease (e.g., in an in 25 vivo setting). The term "substantially acid resistant" as used herein refers to nucleic acid molecules that are resistant to acid degradation as compared to unmodified nucleic acid molecules. Typically, the relative acid resistance of a nucleic acid will be measured by comparing the percent degradation of a resistant nucleic acid with the percent degradation of its unmodified counterpart 30 (i.e., a corresponding nucleic acid of the same length and sequence having a "normal" backbone and bases). A nucleic acid that is acid resistant is preferably at least one and a half times more resistant to acid degradation, more preferably at least two times more resistant, even more preferably at least five times more resistant, and most preferably at least ten times more resistant than their unmodified counterpart. -18- WO 2008/005002 PCT/US2006/025657 aathbaghveertam-acm resistant nucleic acid molecules exhibit marked acid stability and endonuclease resistance, they are sensitive to 3' exonucleases. In order to enhance the exonuclease resistance of 2'-O-alkyl substituted nucleic acid molecules, the 3' or 5' and 3' ends of the nucleic acid are preferably attached to a chemical moiety that provides an exonuclease 5 blocking function. For example, one or more phosphorothioate nucleotides can be placed at either end of the RNA or DNA. Additionally, one or more inverted bases can be placed on either end of the RNA or DNA, or one or more alkyl or alcohol (e.g., butanol-substituted) nucleotides or chemical groups can be placed on one or both ends. Accordingly, a preferred embodiment of the present invention is a nucleic acid comprising a nucleic acid having the following structure: 10 A-B-C, wherein "B" is a 2'-O-alkyl or 2'-O-alkyl-n(O-alkyl) substituted RNA between about 1 and about 98 bases in length, and "A" and "C" are respective 5' and 3' end blocking groups (e.g., one or more phosphorothioate nucleotides (but typically fewer than six), inverted base linkages, or alkyl, alkenyl, alkynyl, 0-alkyl, and O-alkyl-n(O-alkyl) groups or substituted nucleotides). A partial list of blocking groups includes inverted bases, dideoxynucleotides, methylphosphates, 15 alkyl groups, aryl groups, cordycepin, cytosine arabanoside, 2'-methoxy, ethoxy nucleotides, phosphoramidates, a peptide linkage, dinitrophenyl group, 2'- or 3'-O-methyl bases with phosphorothioate linkages, 3'-0-methyl bases, fluorescein, cholesterol, biotin, acridine, rhodamine, psoralen, glyceryl, methyl phosphonates, butanol, butyl, hexanol, and 3'-O-alkyls. An enzyme-resistant butanol preferably has the structure OH--CH 2

CH

2

CH

2

CH

2 (4 20 hydroxybutyl), which is also referred to as a C4 spacer. The term "substantially nuclease resistant" refers to nucleic acid molecules that are resistant to nuclease degradation, as compared to naturally occurring or unmodified nucleic acid molecules. Modified oligonucleotides of the invention are at least 1.25 times more resistant to nuclease degradation than an unmodified nucleic acid having the same sequence and number of 25 nucleotides, more preferably at least 2 times more resistant, even more preferably at least 5 times more resistant, and most preferably at least 10 times more resistant than their unmodified counterpart. Such substantially nuclease resistant nucleic acid molecules include, but are not limited to, nucleic acid molecules with modified backbones such as ethylphosphotriesters, 2'-0 methylphosphorothioates, 2'-O-methyl-p-ethoxy ribonucleotides, 2'-O-alkyls, 2'-O-alkyl-n(O 30 alkyl), 2'-fluoros, 2'-deoxy-erythropentofuranosyls, 2'-O-methyl ribonucleosides, 3'-O methylribonucleotides, inverted bases (e.g., inverted T's), or chimeric versions of these backbones. The modified oligonucleotide includes RNA or DNA comprising modifications to the sugar moieties such as 2'-substituted or 3'-substituted ribonucleotides, or deoxyribonucleotide 35 monomers, any of which are connected together via internucleoside linkages. Modified RNA or -19- WO 2008/005002 PCT/US2006/025657 Di of PNA or morpholino modified backbones where specificity of the sequence is maintained. The ribose groups and the internucleoside linkages link the bases in a nucleic acid and are referred to as the nucleic acid backbone. A modified backbone includes modifications to the 5 chemical linkage between nucleotides, as well as other modifications that may be used to enhance stability and affinity, such as modifications to the sugar structure. For example, an L anomer of deoxyribose may be used, where the base is inverted with respect to the natural D anomer. In one embodiment, the 2'-OH of the sugar group may be altered to 2'-halogen, 2'-O alkyl or 2'-O-alkyl-n(O-alkyl), which provides resistance to degradation without compromising 10 affinity. Other suitable modified backbones include the following types of internucleotide linkages: 2'-O-methyl-phosphodiesters, 2'-O-alkyl, 2'-O-ethyl, 2'-O-propyl, 2'-O-butyl, 2'-0 alkyl-n(O-alkyl), 2'-methoxyethoxy, 2'-fluoro, 2'-deoxy-erythropentofuranosyl, 3'-O-methyl, p isopropyl oligonucleotides, 2'-O(CH 2

CH

2 )xCH 3 , and/or butyne linkages. An oligonucleotide may have combinations of such modified backbones, may be completely modified, or may comprise 15 all or some linkages being phosphodiester linkages. Preferred internucleoside linkages on the modified oligonucleotide are achiral. The term "achiral" as used herein, refers to a molecule that is superimposable with its mirror image, whereas the term "chiral" refers to a molecule that is not superimposable with its mirror image. Oligonucleotides containing achiral 5' to 3' internucleoside phosphate linkages have 20 internucleotide linkages which are achiral (i.e., no stereochemistry). The achiral oligonucleotides preferably contain at least about three to eight contiguous achiral internucleoside linkages, more preferably, nine to ten contiguous achiral internucleoside linkages, even more preferably, eleven to twelve contiguous achiral internucleoside linkages, and most preferably, is completely comprised of achiral internucleoside linkages through the entire contiguous sequence. In another 25 embodiment, the achiral internucleoside linkages are interspersed with chiral internucleoside linkages (e.g., two contiguous achiral linkages followed by one chiral linkage followed by two contiguous achiral linkages; three contiguous achiral linkages followed by one chiral linkage; four contiguous achiral linkages followed by two achiral linkages, etc.). Examples of achiral internucleoside linkages include, but are not limited to, phosphodiester and diphosphorothioate 30 linkages. Achiral RNA and DNA linkages in the backbone are routinely generated during automated synthesis of oligonucleotides if the final structure is a synnetrical molecule (i.e., a phosphate with the same atom attached to both sides). The internucleoside phosphate linkages can be phosphodiester, or 3' to 3', 5' to 2' or 5' to 5' linkages, and combinations of such similar linkages (to produce mixed backbone modified 35 RNA or DNA). The modifications can be internal (single or repeated) or at the end(s) of the -20- WO 2008/005002 PCT/US2006/025657 RNAIME Anl660BTese modifications can include additions to the nucleic acid molecule, such as cholesteryl, diamine compounds with varying numbers of carbon residues between amino groups and terminal ribose, and deoxyribose or phosphate modifications which cleave or cross-link to the opposite chains or to associated enzymes or other proteins. Electrophilic groups 5 such as ribose-dialdehyde could covalently link with an epsilon amino group of the lysyl-residue of such a protein. A nucleophilic group such as n-ethylmaleimide tethered to an RNA or DNA could covalently attach to the 5' end of an mRNA or to another electrophilic site Efficacy of a particular composition may be determined by means known in the art. These include in vitro and in vivo methods, such as, e.g., analysis of expression in cell culture 10 contacted with the compositions, analysis of expression and/or phenotypic characteristics and/or physiological characteristics in an in vivo model, and clinical trials. In vivo models include established animal models for various disorders, as well as normal animals which are tested to determine the effect of a composition. For myostatin and muscle growth regulating compositions, model systems such as those provided in the Examples may be used. 15 C. Compositions Compositions of the present invention include compositions that contain a single gene expression modulating oligonucleotide or combinations of gene-expression modulating oligonucleotides. The oligonucleotides are directed at genes involved in muscle-wasting 20 disorders and/or genes that promote muscle growth where muscle growth is desired. Compositions may include only one type of oligonucleotide, e.g., only antisense oligonucleotides. Compositions may include more than one type (e.g., any combination of antisense oligonucleotides, RNAi, ribozymes, and/or DNAzymes). Compositions may include multiple oligonucleotides directed against multiple areas of a single gene. For example, in some 25 embodiments, the invention provides combinations of oligonucleotides, e.g., antisense oligonucleotides, that target the 5' untranslated region (UTR), the 3'UTR, the start, and/or the termination signal of an mRNA derived from a gene. In some embodiments the gene is a myostatin gene. Compositions may include multiple oligonucleotides directed against more than one gene. Compositions may include multiple oligonucleotides directed against multiple areas 30 of multiple genes. The compositions of the invention typically include more than about one, two, three, four, five, six, seven, eight, nine, 10, 15, 20, 30, 40, 50, 75, or 100 different oligonucleotides. Preferably, the compositions of the invention include about two to about 20 different oligonucleotides. More preferably, the compositions of the invention include about two to about 35 15 different oligonucleotides, and most preferably, the compositions of the invention include -21- WO 2008/005002 PCT/US2006/025657 abbtW ft~ 101diffefent oligonucleotides; or alternatively, compositions of the invention include about two to about eight different oligonucleotides or about two to about six different oligonucleotides. In some embodiment, compositions of the invention include about two to about four different oligonucleotides. Thus, in some embodiments, the invention provides 5 combinations of two or more oligonucleotides targeted to modulating expression of two or more different genes involved in muscle wasting conditions. Exemplary genes to which the antisense oligonucleotides may be directed are listed in Tables 1 and 2. In some embodiments, the invention provides combinations of two or more oligonucleotides, where the oligonucleotides are selected from the group consisting of antisense oligonucleotides, RNAi, ribozymes, and 10 DNAzymes, that are targeted to modulating expression of two or more different genes involved in muscle wasting conditions, where the genes are selected from those listed in Tables 1 and 2. In some embodiments, the invention provides RNAi to myostatin, myostatin receptors, and/or other genes involved in muscle wasting conditions. In some embodiments, the invention provides a combination of RNAis, where the RNAis are inhibitory to at least two of the genes 15 listed in Tables 1 and 2. In some embodiments, the invention provides ribozymes to myostatin, myostatin receptors, and/or other genes involved in muscle wasting conditions. In some embodiments, the invention provides a combination of ribozymes, where the ribozymes are inhibitory to at least two of the genes listed in Tables 1 and 2. In some embodiments, the invention provides DNAzymes to myostatin, myostatin receptors, and/or other genes involved in 20 muscle wasting conditions. In some embodiments, the invention provides a combination of DNAzymes, where the DNAzymes are inhibitory to at least two of the genes listed in Tables 1 and 2. In some embodiments, the invention provides one or more antisense oligonucleotides to myostatin. In some embodiments, the invention provides a combination of antisense 25 oligonucleotides to myostatin that includes at least two different antisense oligonucleotides to myostatin. In some embodiments, the myostatin is selected from the group consisting of human, cow, pig, chicken, mouse, horse, dog, and fish myostatin. In some embodiments, the invention provides a combination of antisense oligonucleotides to different parts of the human myostatin gene transcript, including at least two antisense oligonucleotides targeted to portions of the 30 transcript selected from the group consisting of the 5' UTR, the 3' UTR, the start, and the termination signal. In some embodiments, the invention provides a combination of antisense oligonucleotides to human myostatin, including at least two antisense oligonucleotides selected from the group consisting of SEQ ID NOS. 1 - 191. In some embodiments, the invention provides a composition that includes at least one 35 antisense oligonucleotide targeted to myostatin and at least one antisense oligonucleotide -22- WO 2008/005002 PCT/US2006/025657 tagetetO-anast-one-nonnyostatin gene selected from those listed in Tables 1 and 2. Some embodiments provide combinations of antisense oligonucleotides targeted to myostatin and to two or more other genes listed in Tables 1 and 2. In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to myostatin and at 5 least one antisense oligonucleotide targeted to at least one of NFKB, Cox 2, myo D, a myostatin receptor (e.g., ARIIb), and/or a gene product that converts inactive myostatin to an active form (e.g., TLL2). In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to myostatin and at least one antisense oligonucleotide 10 targeted to myo D. The myostatin and myoD are human in preferred embodiments. In some embodiments, the invention provides a composition that includes at least one antisense oligonucleotide targeted to human myostatin, wherein the sequence of the oligonucleotide is selected from SEQ ID NOs 1 -191. Any of these combinations may include a plurality of antisense oligonucleotides targeted 15 to one or more of the target genes, e.g., combinations of oligonucleotides targeted to the 5' UTR, the 3'UTR, the start signal, and/or the termination signal, of one or more of the target genes. D. Pharmaceutical, nutritional supplement, and homeopathic compositions The invention further provides pharmaceutical, nutritional supplement, and homeopathic 20 compositions. Pharmaceutical compositions The present invention includes pharmaceutical compositions comprising at least about one oligonucleotide as described herein. In some embodiments, the invention provides pharmaceutical compositions that include at least two, three, four, five, six, seven, eight, nine, 10, 15, 20, 30, 40, 50, 75, or 100 different 25 oligonucleotides, as described herein. In some embodiments, the oligonucleotides are antisense oligonucleotides, ribozymes, siRNA, DNAzymes, or a combination thereof. In some embodiments, one or more of the oligonucleotides is a modified oligonucleotide. In some embodiments, the pharmaceutical composition contains one or more antisense oligonucleotides, any or all of which may be modified as described herein. The pharmaceutical compositions 30 further comprise a pharmaceutically suitable excipient. As used herein, the term "pharmaceutical composition" refers to a therapeutic composition that is used to treat a particular disease or pathological disorder that is suitable for parenteral, oral or topical administration in humans. The compositions containing the oligonucleotides of the invention in an admixture with a 35 pharmaceutically acceptable carrier can be prepared according to known techniques. The carrier -23- WO 2008/005002 PCT/US2006/025657 lay tale ftVWme vanety or torms depending on the form of preparation desired for administration, e.g., intravenous, oral, topical, aerosol (for topical or inhalation therapy), suppository, parenteral, or spinal injection. The excipient may contain any number of carriers. In the case of homeopathic pharmaceuticals the carriers would preferably be homeopathic carriers, 5 e.g., homeopathic agents that may increase the efficacy of the homeopathic composition or help to alleviate symptoms associated with a physiological condition. In addition, the composition may contain stabilizers, preservatives, and other ingredients, preferably in amounts from about 0.5 to 2.0 percent by weight, provided they do not adversely affect the ability of the pharmacological composition to treat the physiological condition. It is well within the skill of 10 one in the art to determine an appropriate mode of administration and to select an appropriate delivery system. Administration of the composition will introduce the modified oligonucleotides to the individual in a diluted amount. Exemplary unit dosages for oral or topical administration may be more than about 0.01, 0.05, 0.1, 0.5, 1, or 5 mg/kg, and/or less than about 10, 5, 1, 0.5, 0.1, or 15 0.05 mg/kg. Exemplary unit dosage ranges may be between about 0.01 mg/kg and 10 mg/kg, or between about 0.010 mg/kg and 1.0 mg/kg, or between about 0.10 mg/kg and 1.0 mg/kg for a composition that contains a single oligonucleotide. In some embodiments, the oligonucleotide compositions of the present invention are administered at unit dosages of about 0.01 to about 100 ug per kg of body weight, or about 0.1 to about 100 ug per kg of body weight, or about 0.1 to 20 about 10 ug per kg of body weight, or about 1 to about 10 ug per kg of body weight, or about 1 to about 5 ug per kg of body weight. When more than one oligonucleotide is present in the composition, dosages of each oligonucleotide may be in the latter ranges, or dosage of one or more of the oligonucleotides may be decreased, based on the expected overall effect of the combination. In some embodiments, unit dosages per single oligonucleotide are at or below 100 25 ug per kg of body weight, or at or below 10 ug per kg of body weight, or at or below 1 ug per kg of body weight, or at or below 0.1 ug per kg of body weight, or at or below 0.01 ug per kg of body weight. When orally administered, one dosage unit may be administered once every 10, 9, 8, 7, 6, 5, 4, 3, 2, or one day, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 times per day until relief is 30 achieved or until the symptoms disappear or are satisfactorily attenuated. In some embodiments, one dosage unit is administered about once to about four times per day. In some embodiments,, a patient is instructed to orally take two to three dosage units per day. The dosage unit may be placed under the tongue of the patient or simply swallowed for such oral administration. The pharmaceutical compositions of the present invention may be formulated for 35 administration to humans and animals in liquid form, or in tablets, pills, granules, powders, or in -24- WO 2008/005002 PCT/US2006/025657 n or suppositories. Ointments and creams are impregnated with a low liquid potency or, sometimes, mother tinctures and are generally prescribed as specific remedies. Liquid compositions may be supplied in amber glass dropper bottles to protect them from light. 5 In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations (such as, for example, suspensions, elixirs, and solutions); or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid 10 preparations (such as, for example, powders, capsules and tablets). For administration by injection, preparations may comprise an aqueous solution of a water soluble, or solubilized, and pharmacologically acceptable form of the nucleic acid in an appropriate liquid, e.g., water or saline solution. Injectable suspensions may also be prepared using appropriate liquid carriers, suspending agents, agents for adjusting the isotonicity, 15 preserving agents, and the like. Actual methods for preparing administrable pharmacological compositions and adjustments necessary for administration to subjects will be known or apparent to those skilled in the art. For topical administration, the carrier may take a wide variety of forms depending on the preparation, which may be a cream, dressing, gel, lotion, ointment, or liquid. A surfactant can be 20 included in the composition to provide deeper penetration of the ingredients. Although natural surfactants are preferred, others such as isopropyl myristate can be used. In one embodiment, the composition is a cosmetic composition for topical administration to the skin. As used herein, the term "cosmetic composition" refers to a composition that is applied topically to the skin to improve the appearance of the skin. 25 Aerosols are prepared by dissolving or suspending the nucleic acid in a propellant such as ethyl alcohol or in propellant and solvent phases. The pharmaceutical compositions for topical or aerosol form will generally contain from about 0.001 percent by weight (of the nucleic acid) to about 40 percent by weight, preferably about 0.02 percent to about 10 percent by weight, and more preferably about 0.05 percent to about 5 percent by weight depending on the particular 30 form employed. Suppositories are prepared by mixing the nucleic acid with a lipid vehicle such as theobroma oil, cacao butter, glycerin, gelatin, or polyoxyethylene glycols. The nucleic acid molecule(s) may be combined with a lipid, cationic lipid, or anionic lipid and the active agent delivered via a nucleic acid/lipid emulsion, or a liposomal suspension. By assembling nucleic acid molecules into lipid-associated structures, the nucleic acid molecules 35 may exhibit an increased half-life in vivo. Examples of suitable anionic lipids for use with RNA -25- WO 2008/005002 PCT/US2006/025657 or Al:Iil0e; tutave ioviinited to, cardiolipin, dimyristoyl, dipalmitoyl, or dioleoyl phosphatidyl choline or phosphatidyl glycerol, palmitoyloleoyl phosphatidyl choline or phosphatidyl glycerol, phosphatidic acid, lysophosphatidic acid, phosphatidyl serine, phosphatidyl inositol, and anionic forms of cholesterol. 5 Nutritional supplements As used herein, the term "nutritional supplement" refers to a composition that is intended to supplement the diet. A nutritional supplement includes any dietary substance used in mammals to supplement the diet by increasing total dietary intake; or a concentrate, metabolite, constituent, extract, etc. Nutritional supplement includes any product that is intended for ingestion in tablet, capsule, powder, soft-gel, gel-cap, or liquid form. As used 10 herein, the term "nutritional supplement" is used synonymously with the term "dietary supplement" and "nutraceutical" throughout the specification. The present invention provides a composition which is useful as a nutritional supplement generally, and specifically for those suffering from a muscle wasting condition. The nutritional supplement composition of the present invention include compositions 15 with a single oligonucleotide and/or a combination of about two or more oligonucleotides. The oligonucleotides or combinations of oligonucleotides may be any of those described herein. The use of the nutritional supplement compositions of the present invention can be used to treat any of the aforementioned indications. These agents may be combined in an oral dosage with other well known nutritional supplements and/or non-flavonoid antioxidants (e.g., selenium, vitamin E 20 (tocopherol, particularly alpha-tocopherol), vitamin C (ascorbic acid) and coenzyme Q10). Dietary fiber supplements may also be used in the composition. Other additives may be incorporated in the nutritional supplement of the present invention. Such additives include minerals, (e.g., boron, etc. and trace metals such as zinc, magnesium, manganese, chromium, molybdenum, copper, iron, calcium, and potassium; and 25 other micronutrients such as thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, choline, biotin, inositol, para-aminobenzoic acid, vitamin D, vitamin K, vitamin A). In another embodiment of the invention a dietary fiber supplement such as oat bran or other natural fiber source may also be added to the composition. Typically the nutritional supplement will further include a pharmaceutically acceptable 30 carrier such as lactose, glucose, sucrose, corn starch, potato starch, cellulose acetate, ethyl cellulose, etc. Diluents and other additives such as one or more pharmaceutically acceptable binding agents, fillers, supports, thickening agents, taste-improving agents, coloring agents, preservatives, stabilizers, regulators, emulsifiers or mixtures thereof may be used depending on the form of the composition employed. -26- WO 2008/005002 PCT/US2006/025657 hhiti'aittdrihg the aforementioned compositions, the invention also includes a method for orally administering the nutritional supplement composition in dosages effective to aid in the maintenance and improvement of an individual's health. The supplement is preferably administered orally. Suitable forms for the nutritional supplement composition for oral 5 administration include tablets, capsules, lozenges, syrups, granules, solutions and suspensions which contain unit doses of the supplement for administration once or several times a day. The nutritional supplement composition of the invention will typically be administered orally as a liquid, tablet or a capsule. Tablets, gel tabs, capsules, liquid and sustained release formulations can be formulated and prepared according to manufacturing techniques well known in the 10 pharmaceutical industry and in a variety of dosage forms. The amount of oligonucleotides of the invention that is contained in a nutritional supplement depends on the desired nutritional effect. As the modified oligonucleotides described herein are generally very well tolerated, large amounts may be given in the fonn of nutritional supplements. Exemplary dosages include about 0.1 mg/kg to 100 mg/kg per day, or 15 between about 1.0 mg/kg and 50 mg/kg per day, or between about 1.0 and 20 mg/kg per day. As described above, when combinations of oligonucleotides are used, dosages of individual oligonucleotides in the nutritional supplement may be adjusted downward if necessary or desirable. Nutritional supplements of the invention may include modified oligonucleotides, as described herein. 20 Homeopathic compositions In some embodiments, the invention provides homeopathic compositions. Homeopathic compositions may be made by methods known in the art. One exemplary method of making a homeopathic composition comprises (i) triturating solid oligonucleotide of the invention in a 1/9 ratio with lactose to produce a 1X solid and (ii) repeating the process until the desired attenuation is achieved. In a related vein, a method of 25 making a homeopathic composition comprising (i) dissolving 1 part oligonucleotide of the invention by weight in liquid to produce ten volumes of liquid attenuation labeled 1X and optionally (ii) mixing 1 ml of the 1X attenuation with 9 ml of diluent to produce a lower concentration, is also addressed. In some embodiments, the invention includes homeopathic compositions containing 30 modified oligonucleotides. Any oligonucleotide or combination of oligonucleotides described herein may be used in the homeopathic compositions. In one embodiment, tablets for homeopathic use are preferably produced as placebo tablets that are then medicated by dripping or spraying liquid potencies onto the tablets in such a manner as to ensure a coefficient of impregnation of almost 100 percent. The placebo tablets are preferably formed by compression. 35 Pills or granules are preferably spherical in shape, of about 4 millimeters diameter and 3 to 5 -27- WO 2008/005002 PCT/US2006/025657 enegwamnmovfeirg~TlrhyAre preferably prepared (from pure lactose) and medicated in the same manner as tablets. For example, solid oligonucleotides or combinations of oligonucleotides can be triturated (i.e., ground up) in a 1/9 ratio with lactose (1 gram of oligonucleotide+9 grams of lactose) to produce a 1X solid. The process is repeated (1 gram of that material plus 9 grams 5 of lactose) until the desired attenuation is achieved. For homeopathic compositions, the excipient may contain any number of carriers, and preferably homeopathic carriers, e.g., homeopathic agents that may increase the efficacy of the homeopathic composition or help to alleviate symptoms associated with a physiological condition. For example, oligonucleotides or combinations of oligonucleotides can be dissolved in 10 a liquid 1 part by weight to produce a ten volumes of liquid attenuation labeled IX. To produce lower dilutions 1 ml of the 1X attenuation is used (mixed thoroughly) with 9 ml of diluent to produce 2X. This process is repeated until the desired attenuation is achieved. A homeopathic carrier solution such as that described in U.S. Pat. No. 5,603,915 may be used for increasing the efficacy of the homeopathic agent. This carrier solution is sequentially subjected to an alternating 15 current electrical treatment and a direct current electrical treatment, after which additional ingredients such as seawater, brain hormones, and biologically active enzymes are added. The electrical treatment of the carrier, along with the addition of homeopathically active substances, can be used to increase the efficacy of the homeopathic composition. Alternatively, an electromagnetic carrier, such as described in U.S. Pat. No. 5,830,140 may be employed. For 20 homeopathic preparations for example, oligonucleotides or combinations of oligonucleotides can be dissolved in a liquid 1 part by weight to produce a ten volumes of liquid attenuation labeled 1X. To produce lower dilutions 1 ml of the 1X attenuation is used (mixed thoroughly) with 9 ml of diluent to produce 2X. This process is repeated until the desired attenuation is achieved. Typical homeopathic unit doses are given in Table 7. 25 II. Methods of the invention The invention further provides methods of treatment using the compositions of the invention. Methods include methods of modulating gene expression in cells by contacting cells with compositions of the invention. Methods also include methods of treatment of muscle 30 wasting disorders or conditions. As used herein, the term "muscle wasting disorder," used synonymously herein with the term "muscle wasting condition," encompasses disorders or conditions in which muscle wasting is one of the primary symptoms, such as muscular dystrophy, spinal cord injury, neurodegenerative diseases, anorexia, sarcopenia, cachexia, muscular atrophy due to immobilization, prolonged bed rest, or weightlessness, and the like, as 35 well as disorders in which an abnormally high fat-to-muscle ratio is implicated in a disease or -28- WO 2008/005002 PCT/US2006/025657 pre-amease~ svaea edi"6;I diabetes or Syndrome X. Methods include allopathic, nutritional, and homeopathic therapeutic methods. Conventional means of diagnosis may be used to determine the presence and severity of these conditions. In addition, the invention provides methods of increasing muscle mass in animals where such an increase is desirable, e.g., in food 5 animals such as manmals and fish. Also, the compositions described herein can be used as an adjunct to other therapies e.g. those employing other therapeutic agents, dietary modifications, physical therapy, and the like. Atrophy of skeletal muscle occurs in muscles of adult animals as a result of lack of use, aging, starvation, and as a consequence of a variety of diseases, disorders, and conditions such as 10 sepsis, muscular dystrophy, AIDS, aging, and cancer. The loss of muscle is generally characterized by decreases in protein content, force production, fatigue resistance, and muscle fiber diameter. These decreases can be attributed to both a decrease in protein synthesis and an increase in protein degradation. Muscle wasting and related conditions to which the compositions and methods of the invention are directed include any condition in which enhanced 15 muscle growth, or diminishment of muscle wasting, produces a therapeutically or otherwise desirable result. Conditions include muscular dystrophy, sarcopenia, cachexia, diabetes mellitus, and the improvement of muscle mass where such improvement is ethical and desirable, e.g., in food animals. Diseases associated with muscle wasting generally are associated with altered or 20 abnormal expression of a number of genes compared to the normal state. As used herein, the term "abnormal," when used in reference to the amount, development or metabolic activity of muscle or adipose tissue, is used in a relative sense in comparison to an amount, development or metabolic activity that a skilled clinician or other relevant artisan would recognize as being normal or ideal. Such normal or ideal values are known to the clinician and are based on average 25 values generally observed or desired in a healthy individual in a corresponding population. For example, in patients with obesity-related diseases such as diabetes, the clinician would know that obesity is associated with a body weight that is about twenty percent above an "ideal" weight range for a person of a particular height and body type. However, the clinician would recognize that a body builder is not necessarily obese simply by virtue of having a body weight that is 30 twenty percent or more above the weight expected for a person of the same height and body type in an otherwise corresponding population. Similarly, the artisan would know that a patient presenting what appears to abnormally decreased muscle activity could be identified as having abnormal muscle development, for example, by subjecting the patient to various strength tests and comparing the results with those expected for an average healthy individual in a 35 corresponding population. -29- WO 2008/005002 PCT/US2006/025657 :1Id anip sm6Mann methods of the invention target individual genes as well as, preferably, combinations of genes involved in these conditions. By employing combination compositions and therapies, reversible reactions may be avoided, and multiple pathways may be targeted simultaneously, leading to greater therapeutic effect than when single genes are targeted. 5 Toxicity, if any, may be lower by using combination therapies due to potentially lower amounts of each particular gene modulator being used. In addition, combinations of inhibitors, and combinations of targets in single genes are encompassed by the methods of the invention. In general, gene modulators used in compositions and methods of the invention are targeted at genes whose expression is desired to be inhibited; however, in some cases, some of the gene 10 modulators used in embodiments of the invention may result in an increase in expression. The invention also encompasses modified oligonucleotides for use in gene modulation, where the modified oligonucleotides are typically more stable and resistant to degradation than natural oligonucleotides; the modified oligonucleotides of the present invention are less toxic than many presently-used modifications (e.g., S-oligonucleotides), thus allowing dosages to be 15 higher without adverse side effects. A. Muscle wasting conditions The compositions and methods of the invention are of use in conditions where muscle wasting occurs, and/or where increased muscle mass and/or decreased fat mass is desirable. 20 Exemplary conditions of mammals that may be treated by the compositions and methods of the invention include, but are not limited to: Muscular dystrophy The muscular dystrophies are a heterogeneous group of neuromuscular disorders. The diseases include the most common type, Duchenne muscular dystrophy (DMD), multiple types of limb girdle MD (LGMD) and other congenital MDs 25 (CMD). Progressive muscle damage and muscle loss, tissue inflammation and replacement of healthy muscle with fibrous and fatty tissues result in muscle wasting in muscular dystrophy. Extreme muscle loss is one of the most prominent signs of the disease, and leads to complications and symptoms, including death. Sarcopenia Sarcopenia is the age-related loss of muscle mass, strength and function. It 30 begins in the fourth decade of life and accelerates after the age of approximately 75 years. Many factors, including physical inactivity, motor-unit remodeling, decreased hormone levels, and decreased protein synthesis, may all contribute to sarcopenia. With the exception of physical inactivity, all of these may be subject to genetic control where gene modulation may be useful. For example, the rate of muscle protein synthesis and protein breakdown affects sarcopenia. The 35 balance of protein synthesis and breakdown determines the protein content in the body. -30- WO 2008/005002 PCT/US2006/025657 sr e t y orted that muscle protein synthesis rates are lower in older adults when compared to younger adults. A decrease in muscle protein catabolism, effected by, e.g., gene modulation, could result in slowing or reversal of the loss of muscle mass. Cachexia Cachexia is a condition associated with a variety of serious diseases, including 5 cancer, AIDS, septicemia and congestive heart failure. Its major effect is massive loss of both adipose tissue and skeletal muscle, which is not caused by malnutrition. Cachexia contributes to nearly one-third of all cancer deaths. In a process that is not yet well understood, cytokines and tumor factors mediate wasting by suppressing muscle gene products. Cachectic factors have been shown to be selective in targeting the myosin heavy chain. In myotubes and mouse 10 muscles, TNF-alpha plus IFN-gamma strongly reduced myosin expression through an RNA dependent mechanism. Cachexia involves a complex disruption of several systems that also leads to anemia, insulin resistance, immunosuppression, and activation of an acute-phase response. See, e.g., Acharyya et al., J. Clin. Invest. 114:370-78 (2004). The resulting progressive weakness can make patients with cancer more susceptible to the toxic effects of radiation and 15 chemotherapy; many such patients die from cachexia-related syndromes, rather than from their tumors. Thus, the therapies of the present invention aimed at reversal of muscle wasting in cachexia are considered one promising approach to the condition. Diabetes Diabetes mellitus is the most common of the serious metabolic diseases. Obesity and a high body mass index (BMI) are risk factors for diabetes. Type I diabetes, also 20 known as juvenile-onset diabetes, results from destruction of the beta-cells of the pancreas, and generally requires exogenous administration of insulin for treatment. Type II diabetes, also known as adult-onset diabetes, accounts for over 80% of the cases of diabetes, and its incidence is increasing at a rapid rate. In Type II diabetes, onset is generally gradual and is related to a number of factors, including obesity. Type II diabetes can often be ameliorated and in some 25 cases controlled through lifestyle changes, which can include weight loss and increase in skeletal muscle mass. Studies in transgenic mice have shown that alterations in muscle mass and body composition induced by modulation of gene activity can alter the parameters associated with diabetes. For example, the dramatic reduction in overall fat accumulation in myostatin mutant mice as compared to wild type mice indicates that myostatin activity can be manipulated to treat 30 or prevent obesity or type II diabetes. See, e.g., U.S. Patent No. 6,656,475, incorporated by reference herein in its entirety. It will be appreciated by those of skill in the art that the above conditions are merely exemplary of conditions in which modulation of genes involved in muscle wasting by the compositions and methods of the invention may be effective. Other disorders that may be 35 treated by modulation of gene expression involved in muscle wasting include, but are not limited -31- WO 2008/005002 PCT/US2006/025657 tbsih6l Fd iii fiieodegenerative disorders, traumatic injury, congestive obstructive pulmonary disease (COPD), anorexia, AIDS, atrophy due to immobilization, bed rest, or weightlessness, and any other disorder in which there is a disruption of normal skeletal muscle mass or strength. In accordance with the present invention, genes whose expression is altered in 5 these disorders, or whose modulation would achieve therapeutic benefit even if their expression is not directly altered, e.g., myostatin, myostatin regulatory elements, and the like, may be modulated to achieve muscle specific expression of a target gene to promote muscle growth and increase muscle mass for the treatment of a muscle associated disorder. Other genes that are abnormally expressed, or whose modulated expression promotes a therapeutic effect for the 10 condition, may be separately or simultaneously modulated by the methods and compositions of the invention. B. Gene targets for therapy Gene targets for therapy include, but are not limited to, those genes summarized in 15 Tables 1 and 2, and described more fully below. Myostatin Myostatin is a major gene involved in regulating muscle growth that may be involved, directly or indirectly, in almost every muscle wasting condition. As a secreted growth factor, myostatin acts as a negative regulator of skeletal muscle mass in mammals and other animals. Myostatin is almost exclusively expressed in the skeletal muscle lineage, where it 20 negatively regulates myocyte differentiation/growth and determines muscle size. It is a member of the transforming growth factor # family and is expressed in both developing and adult muscles. During development, myostatin is initially expressed in the myotome layer of somites, which give rise to skeletal muscle. In adults, myostatin is expressed in all skeletal muscles. Mice lacking the myostatin gene have 25-30% increased muscle mass. See, e.g., McPherron et al., 25 (1997) Nature, 387 (6628), 83-90. Individual muscles, such as the pectoralis and quadriceps, of myostatin mutant mice are 2-3-fold heavier than those of wild type mice. See, e.g., Whittemore et al. (2003) Biochem. Biophys. Res. Commun., 300(4), 965-97 1, and Grobet et al. (2003) Genesis, 35(4), 227-238. This modulation occurs both in early development and in adults. Blockage of myostatin 30 function in adult mice using a myostatin antibody or conditional knockout technology results in the increment of muscle mass. Like endocrine hormones, myostatin circulates in the serum in high amounts. An increased level of myostatin has been reported in disease conditions with muscle wasting. Thus, myostatin is regarded as a unique drug target and therapeutics that modulate skeletal muscle growth would be useful for disease conditions such as muscular 35 dystrophy, sarcopenia, cachexia, diabetes, and similar muscle-wasting disorders. -32- WO 2008/005002 PCT/US2006/025657 kdAtly, atidb~dy4,in6diated myostatin blockage in mdx mice was employed for the improvement of dystrophy. Blocking myostatin in mdx mice not only increased the number of normal muscle cells but also augmented muscle strength. The mechanism by which myostatin blockage resulted in the recovery of muscle function is not clear, but, without being limited by 5 theory, it is proposed that balancing the muscle loss by wasting with increased muscle mass by myostatin blockage would be beneficial for dystrophic muscles. Since myostatin blockage is effective for increment of muscle mass even in adults, myostatin blockers are also promising as a treatment for dystrophy and other muscle wasting diseases. In sarcopenia, serum myostatin increases in human aging associated with muscle wasting, 10 and has been viewed as a biomarker of age associated sarcopenia. The human myostatin gene product is proposed to be a suppressor of skeletal muscle growth with advancing age. Thus, myostatin blockage would be beneficial for preventing sarcopenia. In addition, even if myostatin is not directly implicated in a disorder, its modulation is useful in that it may serve as an alternative pathway for stimulating muscle growth, bypassing a 15 pathway that may be blocked or modified in a particular disorder. Myostatin receptors Signaling of myostatin is similar to that of activins and TGF-fl. It efficiently binds the type II receptor ActRIIB and forms a heteromeric complex with the type I receptor ALK4 or ALK5, which leads to phosphorylation of the members of Smad family to control gene transcription and mediates the effects of myostatin. Smads are a family of signaling 20 molecules that transmit signals from cell surface receptors directly to the nucleus. In the nucleus, they regulate transcription by interacting with both DNA elements and transcriptional coactivators and corepressors. Smads binds numerous transcriptional regulators like p53, CBP and the fos/jun family and are involved in cell-type specific gene expression. Transcription factors Myogenic transcription factor MyoD is a putative regulator of the 25 actions of myostatin. A family of transcription factors specifically expressed in the muscles, including myoD, myogenin, myf-5, and MRF-4/herculin/myf-6, have been cloned. These factors are phosphorylated nuclear proteins containing a helix-loop-helix (bHLH) motif, as required for both dimerization and DNA binding, and are believed to be determinants of the cell-specific differentiation program. When one of these factors is introduced into non-myogenic cells, 30 differentiation into mature muscle cells is initiated. The myoD family, a group of transcription factors, has been found to direct muscle formation, inhibit proliferation, activate differentiation and induce a contractile phenotype. While myoD and myf-5 are expressed within the proliferating myoblasts, myogenin and MRF-4 are not expressed until the myoblasts withdraw from the cell cycle in response to mitogen withdrawal. Based on these findings, it was -33- WO 2008/005002 PCT/US2006/025657 cIemonstrateatnamyogenln and IRF-4 activate and maintain the expression of muscle-specific genes, while myoD and myf-5 are thought to play a role in the proliferation of myoblasts. The dystrophin gene The compositions and methods of the invention may include a gene modulator, e.g., an antisense oligonucleotide, that causes a change in the mutation seen in 5 Duchenne muscular dystrophy (DMD) to a in-frame mutation. DMD, the most severe form of the disease, results from an abnormality in exon 19 of the dystrophin gene, which causes an out of-frame shift of the amino acids reading frame of dystrophin mRNA. In contrast, in Becker muscular dystrophy (BMD), a much milder form of the disease, the reading frame is kept intact (i.e., in-frame) in spite of a partial deletion present in the gene and a dystrophin protein therefore 10 is synthesized, though it differs in size from wild dystrophin. If the abnormal reading frame shift of DMD is converted to an in-frame arrangement, then DMD is converted to BMD, and amelioration of the symptoms would be expected. Exon 19 skipping can be artificially induced by administering to the patient an antisense oligonucleotide against exon 19, thus, the reading frame could turn in-frame again because of the total loss of 330 nucleotides from the pre-mRNA 15 due to the loss of 242 nucleotides of exon 20 plus 88 nucleotides of exon 19. It has been demonstrated that splicing out of exon 19 can be induced with an antisense oligonucleotide against exon 19 in the cells of a DMD patient having complete loss of exon 20 in mature dystrophin mRNA, and that the existing shift of the reading frame along the mature dystrophin mRNA can thereby be corrected, thus converting the dystrophin-negative cells to 20 positive ones. Based on these results, antisense oligonucleotides targeted at parts of the dystrophin gene have been proposed as treatment of DMD. See, e.g., Japanese Laid-open Patent Application No. 11-140930, and U.S. Patent Nos. 6,727,355; and 6,653,467 all of which are incorporated herein by reference. Accordingly, the compositions and methods of the invention may include a gene modulator, e.g., an antisense oligonucleotide, that causes a change in the 25 mutation seen in DMD to a in-frame mutation. Genes involved in cachexia Various pathways and modulators may be involved in cachexia. The fever-producing cytokines released by inflammatory cells and tumor cells are believed to contribute to cachexia. In fact, tumor necrosis factor (TNF), or cachectin, produces a laboratory model of cachexia when given to experimental, laboratory animals. Activins and 30 myostatin are up-regulated in several types of cancer and infection, and could be therapeutic targets for cachexia. Myostatin has been shown to be involved in different types of cachexia. Myostatin administration in vivo induces severe weight loss and decreased muscle mass. In addition, accelerated proteolysis in muscle in fasting or denervation atrophy can be due to activation of the nonlysosomal (cytosolic) ATP-ubiquitin-dependent proteolyte process. The 35 proteins involved in this process are potential targets for gene modulators. See, e.g., U.S. Patent -34- WO 2008/005002 PCT/US2006/025657 lo.5',9 , , ifli§hido!*porated herein by reference in its entirety. In fasting, the enhancement of muscle protein breakdown also requires glucocorticoids and low insulin and in febrile infections, requires interleukin-1 and TNF. A novel protein, cancer cachectic factor, also may be involved in the cachexia of, e.g., cancer, and presents another target for gene modulators 5 as therapy. See, e.g., U.S. Patent No. 5,834,192, which is incorporated herein by reference in its entirety. Diabetes Since proper skeletal muscle function is important for normal glucose homeostasis, loss of activity of myostatin not only increases muscle mass but also prevents an age-related increase in the total mass of adipose tissues. Myostatin-deficient mice showed a 10 reduction in fat accumulation with increasing age. The activin-follistatin system was also shown to be involved in development of the pancreas. It was suggested that follistatin's modulation of the formation of the exocrine pancreas was by inhibiting activin-like signaling molecules. Recently, using functional genomics tools, several secreted polypeptides with therapeutic applications in the treatment of diabetes, and BMP 9 were identified as potential inhibitors of 15 glucose production and glycemia. Thus, in addition to adipocytokines such as leptin and adiponectin, multiple TGF-3 family members including myostatin, activin and BP 9 are involved in glucose homeostasis and diabetes. Obese and insulin resistant mice with myostatin KO have less fat accumulation, low blood glucose and low insulin than their counterparts with wild-type myostatin, which led to the suggestion that inhibition of myostatin may be a treatment 20 for type 2 diabetes mellitus. In some embodiments, the invention provides methods of modulating the expression of one or more genes in cells by contacting cells with compositions of the invention. In these methods, cells to be treated contain a polynucleotide encoding a gene product that is involved in a muscle-wasting condition, or in muscle growth or muscle growth inhibition. Representative 25 polynucleotides are shown in Tables 3, 4 and 5. The cell is contacted with any one of the compositions of oligonucleotides described herein for modulating expression of one or more polynucleotides. In some embodiments, the cell contains a polynucleotide encoding myostatin, myostatin transcription factor, myostatin activating protein, and/or myostatin receptor, and the composition with which the cell is contacted contains one or more oligonucleotides capable of 30 modulating the expression of myostatin, myostatin transcription factor, myostatin activating protein, and/or myostatin receptor. A method of the invention can be performed, for example, by contacting under suitable conditions a target cell and an oligonucleotide composition of the invention. Suitable conditions can be provided by placing the cell, which can be an isolated cell or can be a component of a 35 tissue or organ, in an appropriate culture medium, or by contacting the cell in situ in an -35- WO 2008/005002 PCT/US2006/025657 ofganii eddu containing the cell can be contacted with an oligonucleotide composition that, e.g., modulates expression of myostatin, myostatin signal transduction, myostatin receptors, myostatin transcription factors, myostatin-activating gene products, and the like. In general, the cell is a component of a tissue or organ in a subject, in which case 5 contacting the cell can comprise administering the agent to the subject. However, the cell also can be manipulated in culture, then can be maintained in culture, administered to a subject, or used to produce a transgenic nonhuman animal. The level of mRNA expression of the target gene in the cell, tissue, organ, or animal, may be assessed using techniques that are known in the art, including, but are not limited to, Northern or Western blot analysis of tissue samples 10 obtained from the cell, tissue, organ, or animal in situ hybridization analysis, and RT-PCR. Samples of cell, tissue, organ, or animal, may also be evaluated immunocytochemically using antibodies specific for the target gene product. The present invention also provides methods, compositions, and kits for the treatment of animals. The term "animal" or "animal subject" as used herein includes humans as well as other 15 mammals and non-mammals. The term "treating" and its grammatical equivalents as used herein include achieving a therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant eradication, amelioration, or prevention of the underlying disorder being treated. For example, in a diabetes patient, therapeutic benefit includes eradication or amelioration of the underlying diabetes, i.e., a return of blood sugar and blood insulin levels to normal or a trend 20 toward normal. Also, a therapeutic benefit is achieved with the eradication, amelioration, or prevention of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder. For example, administration of oligonucleotide compositions, described herein, to a patient suffering from muscular dystrophy, sarcopenia, 25 spinal cord injury, neurodegenerative disease, anorexia, or cachexia, provides therapeutic benefit when an improvement is observed in the patient with respect muscular bulk, muscular strength, and the like. For prophylactic benefit, for example, the compositions of the invention may be administered to a patient at risk of developing a muscle wasting condition, for example, a patient undergoing prolonged bed rest, or to a patient reporting one or more of the physiological 30 symptoms of a muscle wasting disorder, or suffering from a conditions that predisposes the patient to a muscle wasting disorder, even though a diagnosis of a muscle wasting disorder may not have been made. For example, the oligonucleotide compositions of the invention may be administered to a patient with cancer where cachexia has not been diagnosed. In another example, compositions of the invention may be administered to a patient exhibiting Syndrome X 35 who does not yet exhibit clinical symptoms of diabetes such as resting blood glucose elevated -36- WO 2008/005002 PCT/US2006/025657 A0e.ME Ci1 0 6i klif d threshold value for diabetes. Thus, the method of treating of the present invention covers any treatment of symptoms of a disorder in an animal, preferably a mammal, particularly a human, and includes: (a) preventing symptoms of a disorder from occurring in a subject that may be 5 predisposed to a condition but has not yet been diagnosed as having it; (b) inhibiting symptoms of a disorder (i.e., arresting its development); or (c) relieving symptoms of a disorder (i.e., ameliorating and/or causing regression of the condition); and/or (d) maintaining homeostasis (i.e., the normal balance of RNA or DNA in a 10 subject). One of ordinary skill will appreciate that, from a medical practitioner's or patient's perspective, virtually any alleviation or prevention of an undesirable symptom would be desirable. The dosages of the oligonucleotide composition in animals will depend on the disease or 15 condition being, treated, the route of administration, and the physical characteristics of the animal being treated, and whether the treatment is nutritional, allopathic, or homeopathic. The compositions of the present invention are formulated to contain a "nutritionally effective" or "allopathically effective" or "homeopathically effective" amount of one or more nucleic acid molecules. As used herein, the term "nutritionally effective" amount is meant to 20 refer to an amount of a oligonucleotide composition that is non-toxic and greater than the minimum amount necessary to maintain a desired physiological effect. As used herein, the term "allopathically effective" amount is meant to refer to an amount of a oligonucleotide composition that is non-toxic and greater than the minimum amount necessary to produce a desired physiological effect. As used herein, the term "homeopathically effective" amount is meant to 25 refer to an amount of a oligonucleotide composition that is non-toxic and is the lowest amount necessary to provide a desired physiological effect. A homeopathic effect, in accordance with the present invention, is achieved by a dose of modified nucleic acid that will be effective in treating (i.e., relieving, ameliorating, or preventing) symptoms of a particular condition or disease. Such treatment may be prophylactic in nature (i.e., completely or partially preventing 30 the future occurrence of a symptom) and/or it may be therapeutic in nature (i.e., providing a partial or complete cessation or amelioration of a symptom). Accordingly, in embodiments wherein the treatment utilizes allopathically effective amounts of compositions, the oligonucleotide compositions of the present invention may be administered at a unit dosage more than about 0.01, 0.05, 0.1, 0.5, 1, or 5 mg/kg, and/or less than 35 about 10, 5, 1, 0.5, 0.1, or 0.05 mg/kg. Exemplary unit dosage ranges may be between about -37- WO 2008/005002 PCT/US2006/025657 -0.0'1 Mkd'dl ~iglbf between about 0.010 mg/kg and 1.0 mg/kg, or between about 0.10 mg/kg and 1.0 mg/kg for a composition that contains a single oligonucleotide. In some embodiments, the oligonucleotide compositions of the present invention are administered at unit dosages of about 0.01 to about 100 ug per kg of body weight, or about 0.1 to about 100 ug per kg 5 of body weight, or about 0.1 to about 10 ug per kg of body weight, or about 1 to about 10 ug per kg of body weight, or about 1 to about 5 ug per kg of body weight. When more than one oligonucleotide is present in the composition, dosages of each oligonucleotide may be in the latter ranges, or dosage of one or more of the oligonucleotides may be decreased, based on the expected overall effect of the combination. In some embodiments, unit dosages per single 10 oligonucleotide are at or below 100 ug per kg of body weight, or at or below 10 ug per kg of body weight, or at or below 1 ug per kg of body weight, or at or below 0.1 ug per kg of body weight, or at or below 0.01 ug per kg of body weight. When orally administered, one dosage unit may be administered once every 10, 9, 8, 7, 6, 5, 4, 3, 2, or one day, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 times per day until relief is 15 achieved or until the symptoms disappear or are satisfactorily attenuated. In some embodiments, one dosage unit is administered about once to about four times per day. In some embodiments,, a patient is instructed to orally take two to three dosage units per day. The dosage unit may be placed under the tongue of the patient or simply swallowed for such oral administration. Modified oligonucleotides as described herein, e.g., achiral oligonucleotides of naturally 20 occurring phosphodiester DNA and RNA linkages with 3' nuclease protection and sometimes also 5' nuclease protection, are not toxic, allowing a wide range of dosages to be possible with compositions of the present invention. For example, the dietary supplement recommendation for nucleic acids is 0.5 to 2.0 gm/day. Metabolites are naturally occurring compounds that occur in foods and as byproducts of cell catabolism. Furthermore, such compounds do not elicit an 25 immune response. Accordingly, in some embodiments, dosages range from about 10 ug to 100 mg/kg/per day, or 0.01 gm to 10 gm/kg per day, or 0.01 to 1 gm/kg/day, or 0.01 to 0.1 gm/kg/day. Homeopathic compositions typically employ substantially less nucleic acid than is employed in allopathic or nutritional compositions. Exemplary dosages to be employed in 30 accordance with the present invention are described in Table 7. Furthermore, for homeopathic use, the oligonucleotide compositions of the present invention can be combined with any homeopathic drug and still elicit a therapeutic effect. Oligonucleotide compositions of the present invention may be co-administered with other active pharmaceutical agents depending on the condition being treated. Pharmaceutical agents 35 useful in the treatment of muscle wasting disorders, their optimal dosages and routes of -38- WO 2008/005002 PCT/US2006/025657 admt sdhi~ t M , 4re~kidibtn the art. Co-administration can include simultaneous administration of the two agents in the same dosage form, simultaneous administration in separate dosage forms, and separate administration. In addition, oligonucleotide compositions of the present invention may be used in conjunction with other therapies, such as dietary therapy, dietary 5 supplementation, physical therapy, exercise, and the like, which are used in the treatment of the disorders described herein. The oligonucleotide composition can be administered by injection, topically, orally, transdermally, or rectally. Preferably, the composition is administered orally. The oral form in which the oligonucleotide is administered can include powder, tablet, capsule, solution, or 10 emulsion. The effective amount can be administered in a single dose or in a series of doses separated by appropriate time intervals, such as hours. In some embodiments, one or more of the oligonucleotides comprises at least one modification according to the present invention. A preferred modification is the incorporation of at least about three to eight contiguous achiral internucleoside phosphate linkages into the 15 oligonucleotide backbone, or at least about nine to ten continuous achiral internucleoside phosphate linkages or at least about eleven to fifteen achiral internucleoside phosphate linkages, or the entire oligonucleotide contains achiral internucleoside phosphate linkages. In some embodiments the oligonucleotide is 3' end-blocked. The methods of the present invention can be used to treat disorders including, but not 20 limited to, muscular dystrophy, spinal cord injuries, neurodegenerative diseases, atrophy due to immobilization, bed rest, or weightlessness, sarcopenia, cachexia, and diabetes. Table 6 lists the target genes or combinations of target genes that are preferably employed in preparation of gene modulating compositions of use in remedies for the treatment of various symptoms and conditions. In Table 6, the use a combination of target genes is denoted by a "/" (for example, 25 "A/B/C" denotes the combination of target genes A, B and C); where two or more different combinations are preferred, each such combination is presented on a separate line. The gene modulating compositions targeted at the genes are usually used in a 1:1:1 ratio, but this can vary. For example, in homeopathic treatments, a combination of 4X, 5X, and 6X solutions may be used, which deviates from 1:1:1. Any other ratio of compositions may also be used in 30 combinations, depending on the condition to be treated, the state of the subject, and other factors that are known in the art. Preferably, animals, e.g., mammals, are treated using compositions of the present invention having agents with compositions containing nucleic acid molecules having a sequence appropriate for the particular animal. Targeted species include, but are not limited to birds, fish, 35 and mammals (especially chickens, pigs, goats, sheep, cows, dogs, horses, cats, and most -39- WO 2008/005002 PCT/US2006/025657 pe- sill in the art can determine if a particular therapeutic course of treatment is successful by several methods known to those of skill in the art, including muscle fiber analysis or biopsy. In a further aspect, the invention provides methods of increasing muscle mass of an 5 animal where such an increase is desirable, e.g., in food or non-human sport animals, by administering to the animal an oligonucleotide composition of the invention, e.g., to modulate the expression of the myostatin gene. These methods produce animals having increased muscle and protein content, and, when the animals are used for food, also advantageously the muscles have reduced fat content. Oligonucleotide-based compositions as described herein that directly or 10 indirectly regulate the expression of the myostatin region may be used to reduce expression of the myostatin gene product. Such oligonucleotide compositions may be administered to a livestock animal, including but not limited to cattle, sheep, pig, turkey, chicken, and fish, or to companion animals, particularly cats and dogs, to result in the decreased expression of myostatin in the animal and consequent higher than normal levels of muscle tissue, preferably without 15 increased fat and/or cholesterol levels. A polynucleotide encoding a promyostatin or myostatin, or myostatin transcription factor, receptor, signal transduction factor, myostatin activating gene product can be derived from any organism where increased muscle mass may be desirable, preferably a food, sport or research animal, including, for example, mouse, rat, cow, pig, chicken, turkey, zebrafish, salmon, finfish, other aquatic organisms and other species. Examples 20 of aquatic organisms include those belonging to the class Piscina, such as trout, char, ayu, carp, crucian carp, goldfish, roach, whitebait, eel, conger eel, sardine, flying fish, sea bass, sea bream, parrot bass, snapper, mackerel, horse mackerel, tuna, bonito, yellowtail, rockfish, fluke, sole, flounder, blowfish, filefish; those belonging to the class Cephalopoda, such as squid, cuttlefish, octopus; those belonging to the class Pelecypoda, such as clams (e.g., hardshell, Manila, 25 Quahog, Surf, Soft-shell); cockles, mussels, periwinkles; scallops (e.g., sea, bay, calloo); conch, snails, sea cucumbers; ark shell; oysters (e.g., C. virginica, Gulf, New Zealand, Pacific); those belonging to the class Gastropoda such as turban shell, abalone (e.g. green, pink, red); and those belonging to the class Crustacea such as lobster, including but not limited to Spiny, Rock, and American; prawn; shrimp, including but not limited to M. rosenbergii, P. styllrolls, P. indicus, P. 30 jeponious, P. monodon, P. vannemel, M. ensis, S. melantho, N. norvegious, cold water shrimp; crab, including, but not limited to, Blue, rook, stone, king, queen, snow, brown, dungeness, Jonah, Mangrove, soft-shelled; squilla, krill, langostinos; crayfish/crawfish, including, but not limited, to Blue, Marron, Red Claw, Red Swamp, Soft-shelled, white; Annelida; Chordata, including, but not limited to, reptiles such as alligators and turtles; Amphibia, including frogs; 35 and Echinodermata, including, but not limited to, sea urchins. -40- WO 2008/005002 PCT/US2006/025657 MMth s tI'kIm a ing muscle mass in an animal where such increase is desirable are essentially the same as those used in treating disorders. Dosages, routes of administration, and durations of treatment may be adjusted as desired to produce the optimum development and timing of development, as appropriate for the use of the animal. 5 Table 1:Exemplary human target genes involved in muscle wasting conditions Genes Accession Number Myostatin AF104922 MyoD NM002478 ARIb NMOO1106 TLL2 AF059516 ID-1 NM002165 TACE NM003183 TNF-R1 NM001065 IL6R NM000565&NM181359 MMP2 NM004530 FOXO1 NM002015 Bc1-3 NM005178 FOXO-3 NMOO1455&NM201559 E3alphaII AY061884 Nfkb-1 NM003998 ILlb NM000576 NF-IL6 M83667 NF-B M62399&L19067 TNF-a NM000594 Caspase-3 NM004346 Caspase-1 NM033292 Atrogin-1 NM058229&NM148177 Smad-2 AF027964 PIF AY90150 IL-6 NMOO0600 -41- WO 2008/005002 PCT/US2006/025657 Table 2: Exemplary animal target genes involved in muscle growth and development Genes Accession Number Myostatin (Cow) NMOO1001525 Myostatin (Horse) AB033541 Myostatin (sheep) AF019622 Myostatin (goat) AY436347 Myostatin (Rabbit) AY169410 Myostatin (Pig) NM214435&AF033855 Myostatin (Chicken) AF019621&AF346599 Myostatin (Dog) AY367768 Myostatin (Fish) AY825248 Myostatin (Mouse) NM01834 TLII (mouse) AF073526 AcRIIB (mouse) NM007397 MyoD1 (mouse) NM010866 Atrogin-1 (mouse) AF441120 E3alpha-II (mouse) XM358323 Foxo3 (mouse) NM019740 Foxol (mouse) NM019739 MuRF1 (mouse) AF294790 Caspase3 (mouse) NM009810 NFkB (mouse) NM003998 TNF-alpha (mouse) NM013693 TNF-R1 (mouse) NMO 11609 Caspase-1 (mouse) BC008152 TACE (mouse) AB021709 IL-1b (mouse) NM008361 IL-6 (mouse) NM031168 MMP2 (mouse) NM008610 -42- WO 2008/005002 PCT/US2006/025657 p65 (mouse) M61909 IL-6R (mouse) X53802 Smad2 (mouse) NM010754 Gathepsin-B (mouse) BC006656 Table 3: Antisense oligonucleotides targeted at human genes involved in muscle wasting Genes Accession number Antisense oligonucleotide sequences Seq ID# 5 '-TgCCACACCAgTgAATCT-3' 1 Myostatin AF104922 5'-gCAgTTTTITgCATgATTTTAA-3' 2 5 '-TAAATCTCATgAgCACGC-3' 3 5 '-CAgAgAgTggCCggAACT-3' 4 5 '-TggCg~ggCACggTCCTg-3' 5 MyoD NM002478 5 '-AgTAgCTCCATATCCTgg-3' 6 5 '-AgAgCACGTggTATATCg-3' 7 5 '-CAgggCgCCgTCATgTTC-3' 8 ARM ~ NMOO1 106 5 '-gggTggGTCgTACgTgAC-3' 9 5 '-TgTCCTgggCTTAgATgC-3' 10 5 '-gCggCgGCCGTgTCYJ'C-3' 11 5 '-AgggAgTTgCgTgCACgA-3' 12 TLL2 AF059516 5 '-ggCATggTgg~gCggggC-3' 13 5 -TCCCAgggCTgTgCAggA-3' 14 5 '-AgCCCgAAgCAgATACgg-3' 15 ID-i NM002165 5 '-TCATgATTCTTggCgACT-3'_ 16 5 '-CATgATTCTTggCgACTg-3' 17 5 '-CCACTggCgAGTTTCATg-3' 18 ID-i NM002165 5 '-TCAgCgACACAAgATgCg-3' 19 5 '-GUTCAgCgACACAAgATg-3' 20 TACE NM0O3 183 5 -TTCTACCgCCAggCT~gA-3' 21 5 '-ACTgCCTCATgTTCCCgg-3' 22 ________ ___________5 -CGTCATgTTCCCggCGCC-3' 23 -43- WO 2008/005002 PCT/US2006/025657 5 '-ACTAAATTAgCACTCTgT-3' 24 5 '-GAgTTgAgggTTgAgACT-3' 25 TNF-R1 NMOO1 065 5 -gCCCATgCCAgACAgGTA-3' 26 5 -gCgCAgCCTCATCTgA-3' 27 5 -TCCCTCTggCCCggCTCA-3' 28 IL6R NMOO0565&NM1 81359 5 -C~gACggCCAgCATgCTT-3' 29 5 '-GATTCTggggAAgAAgTA-3' 30 5 '-CAgCCTCCAgCCACCgCC-3' 31 MMP2 NM004530 5 '-gCCTCCATCgTAgCgCTC-3' 32 5 '-gCAgCCTAgCCAgT~ggA-3' 33 5 '-ggCCgCTTgCTCTCCCCA-3' 34 5 '-AgAgggggAgAACgCAgC-3' 35 FOX01 NM00O2015 5'-CTCggCCATggTgACCCC-3' 36 5 '-ACCCTCAgCCTgAGACCC-3' 37 5 '-gCggggCAT~ggggCATg-3' 38 Bcl-3 NM005178 5 '-gCCCCCCATGCCCCTCA--3' 39 5 '-ggg AgggACgTggA~gC-3' 40 FOXO-3 NMOO 1455&NM2O 1559 5 '-CATCTTCgC~gCCCgC-3' 41 5 '-CGTTGAgCCTggCACCCA-3' 42 5 '-CAATCAgTCCCggAgCCg-3' 43 E3alphaII AY061884 5'-TCCTCCCCAgCgCTACCg-3' 44 S '-CTCTagCTCCgACgCCAT-3' 45 EMalphaII AY06 1884 5 -TTggTggTgCAATAATTA-3' 46 S '-TCTCgCTCACTCTCTCAC-3' 47 5 '-gggAAgggCAggggAAgC-3' 48 Nfkb-1 NM003998 5'-gCgCgggCggAgggAAgC-3' 49 5 '-CTgGCATTCTgAAgC~gg-3' 50 S '-gAAATTgTCAgCAggCTA-3' 51 ILlb NMOO0576 S -gAgAATCCCAgAgCAgCC-3' 52 S '-CCATggCTgCTTCAgACA-3' 53 -44- WO 2008/005002 PCT/US2006/025657 _________5 '-ggTACAgCTGTCTTTAgg-3' 54 5'-AgAgCgCggCCgTCATgg-3' 55 NF-IL6 M83 667 5 -gggAAgggCAggggAAgC-3' 56 5 '-CCTTTTCTAgCCCCGg-3' 57 5 '-gAACAgTJ'CgTCCATg-3' 58 5 '-AgCCATTCGCCggAATTC-3' 59 NF-icB M62399&L19067 5'-gTgCACTACAgACgAgCC-3' 60 5 '-CTgCCATTCTgAAgCCgg-3' 61 S '-ggCCCAgCTgCgACCCgg-3' 62 5 '-gggggTCTgTagTTgCTT-3' 63 5 '-CCAggggAgAgAgggTgg-3' 64 TNF-cL NM000594 5 '-gCTCATggTgTCCTTTCC-3' 65 5 '-CATgCTTTCAgTgCTCAT-3' 66 5 '-gATgTTCgTCCTCCTCAC-3' 67 5 '-AggAgCCgCgTCTgCACT-3' 68 5 '-TTCTACAACCgCCTCACA-3' 69 Caspase-3 NM004346 5 '-TCTCCATggATACCTTTA-3' 70 5 '-ACCAACCATTTCTTTAgT-3' 71 5 '-ACCAACCATTTFCTTAgT-3' 72 Caspase-1 NMv033292 S '-TATTTTAATgTCCTgggA-3' 73 Atrogin-1 NM058229&NM148 177 5 -ggATggggAgACggggCC-3' 74 5 '-ggAATggCATggCACCgC-3' 75 Atrogin-1 NM058229&NM148 177 5 '-TTCTACAACCgCCTCACA-3' 76 5 '-TgTATCgAACCTCCCggC-3' 77 S '-gACgACATgTTC'TTACCA-3' 78 Smad-2 AF027964 5 '-gCAAgATggACgACATgT-3' 79 S '-TTATgACATgCTgTTgAgC-3' 80 5 '-TggTgAAgCTTTATgACA-3' 81 PIE AY90150 5'-CTgTgTgCTggAgTgggT-3' 82 S '-ATgAACCTCATgCTTClg-3' 83 -45- WO 2008/005002 PCT/US2006/025657 5 '-TCTCCTTACAgGTATAgT-3' 84 5 '-CTG1T7gCCCggTgg-3' 85 IL-6 NMvOO0600 5'-AAGgAgTTCATAgCTggg-3' 86 ________ ___________ 5 '-GCATgCTACAT1TIgCCgA-3' 87 Table 4: Antisense oligonucleotide sequences targeted at animal genes involved in muscle 5 growth and development Gene Accession number Antisense oligonucleotide sequences (5'-3') SeqID# CAgATCCgggACAgCAAATgC 88 CCCCCTCTCCCTTTCCCCTIT 89 gCATT=PCTTACACCTCAC 90 CATAGACTGCTAgCTTTlgCA 91 CTgCCATCCAgAgCCACCggA 92 Myostatin (chicken) AFO 19621 &AF346599 TCTgCTTCCA~gTACAAgCAT 93 G'JTgTTCCAggCgCAgTTgC 94 TgCAgTggAggAgCTTflgggT 95 TCgTC'TGCAAAgAgCCAT~g 96 CagACTCCgTaggCATTgTgA 97 Myostatin (chicken) AFO 1962 1&AF346599 TagAgCTAAACTTAAAgAAgC 98 CCgTTgTaggTTTTTggACTT 99 TCTgCCAgATACCAgTgCCTg 100 TgTTTgAgCCAAT1TT'gCAgC 101 gCAAgATCTCgTCCAgTCTCA 102 gTgTCTgTAACTCTgACCTCT 103 CgggTAgCgA.CAACAT~gggA 104 gTgCTATAATCCAgTCCCATC 105 AATTCgCATTCTCCggAgCAg 106 _________________________ CCgGgAgCCTCTgggATT 107 -46- WO 2008/005002 PCT/US2006/025657 TACAgCATgTTL'ATAggggAG 108 A~gATGTACAACCATggCTgg 109 TCATgAgCACgCAACgATC 110 TCTGACgTCAgGCAAAATTGA11 TgCCTgCACTgTCTgAgAgAC 112 TgCI~fgAgTAACgCCAAgC 113 CATgATTTTAAAATCAATAGA 114 TgCAgTTIIgCATgATTTTA 115 CATAgATTTgCAgTThgCA 116 TCAgATCCACgggACCAgCAA 117 ACATgCATTACACAgCCCCTC 118 Myostatin (pig) NM214435&AF033855 TCCAggCgAAgTTTACTgAgg 119 gATCAATCAgTTCCCggAgTG 120 TTCcAAggAgCCATCACTgCT 121 AgAAgATCAgACTCTgTAggC 122 TAAAgAAgCAgCATYI'gggTT 123 TCTTGACgggTCTCAgATATA 124 TgggTTTgATgAgTCTCAggA 125 CagTgCCTgggTTCATgTCAA 126 TgAgCCAATT'JTgCAACACTg 127 TgACCATTGTCATCTAAAgCT 128 ggATTCAgCCCATC'1TCTCCT 129 gAgTgCTCATC ACAgTCgAgT 130 Myostatin (pig) NM2 14435&AF033855 TgGAATAATCCAgTCCCATCG 131 ACAAgATgAgTgTgAgggTAT 132 TgTgggAgTACAgCAggggCC 133 ACCATggCTggAATTTCCCA 134 AATCTCATgAgCACCCACAgC 135 Myostatin (cow) NM001525 gAgTAAcGcCAAgCCAAACgT 136 _________________________TCCCTrgTTCTTACTTCTTCC 137 -47- WO 2008/005002 PCT/US2006/025657 gCAgT'fTIgCATggTTTTAA 138 CCTTCTgCTCgCTgTTCTCAT 139 g=ICCCTCCACAAACATgC 140 TTTgCTgATgTTAggAgCTgT 141 gCTggCATCTCTCTggACATC 142 AtgACCgTTTCCgTCCTggCg 143 g=ICCTTCCACTTgCgTTA 144 CACAgTTgggCCTTTlACTAgT 145 ACACTgTCgCAggAgTCTTgA 146 TCCAgTATACCTTgTACCgTC 147 TCTgCCAAATACCAgTgCCTg 148 AgATCATggCCATTCTCATCT 149 TCCATCTTCTCCTggTTCTgg 150 CCTAgATcTTTIggTgTgTC 151 TagAgggTAACgACAgCATCg 152 TCTCCAGAGCAgTAATTggCC 153 AggAgTAGAgCAgg gCCggC 154 _____________TCATgAACACCCACAgCgATC 155 TgAgTAACgCCAAgCCAA 156 Myostatin (horse) AB033541 CAgTTTTTgCATggTTTT 157 MCATgACACCCACAgCg 158_ TgAgTAA~gCCAAgCCAA 159 Myostatin (sheep) AF019622 CAgTTTTTgCATgg'II 160 MCAT ACACCCACAgCg 161 TgAgTAACgCGAAgCCAA 162 Myostatin (goat) AY43 6347 CAgTTI'TTgCATggTYJ 163 ______________________TPATaAACACAC~ ~ 164 -48- WO 2008/005002 PCT/US2006/025657 Table 5: Antisense oligonueceotides equences targeted at human myostatin gene Antisense oligonucleotide sequences (5'-3' SequencelD# ACTTgCCACACCAgTgAATCT 165_________ TCTTgTTC'TgTTCTCCTT16 gTlgCA iTFLTCATgATlIT 167 ACACAgAgTTgCAgT1TfgC 168 AATCAgCATAAACAggTAAAT 169 AgATCCACTggACCAgCAACA 170 ACACAgCCCCTCTTTTTCCAC 171 gAgCTgT'TTCCAgACgAAgTT 172 AgTggAggAgCTTTgggTAAA 173 TCgCTgCTgTCATCCCTGTgg 174 CCgTTgTagCgTgATAAT~gT 175 AGAAAATCAgACTCTgTAggC 176 CATAgTTggCCTTTACTACT 177 TTgTAggAgTCTCgACgggTC 178 GATAggTTTgATgAgTCTCAg 179 AgTgCCTgggYJ'CATgTCAAg 180 TCTTACACAA~CTCgCC181 A~gCTA~T~ggTTCggT182 gCCCTCTCTCCggTC~g183 gTgTgTCTgTTACCTTgACCT 184 TgTTgAgTgCTCATCACAgTC 185 ATCCAATCCCATCCAAAAgCT 186 TCCAgAgCAgTAATTggCCTT 187 g~gTCC~A~g~TA~~gg188 TggggTA~gCAgggC~g189 T~gCggATTTTCCAATA190 ATATAAATCTCATgAgCACCC 191 *Based on AF104922. -49- WO 2008/005002 PCT/US2006/025657 Table 6: Exemplary combinations of oligonucleotides for treatment of muscle wasting Combinations of oligonucleotides targeting the following genes Myo Myo/myoD Myo/ActRIIB Myo/myoD/ActRIIB Myo/ActRIIB/Smad2 Myo/NF-kB Myo/Atrogin-1 Myo/MuRF1 Myo/Atrogin-1/MuRF1 Atrogin-1/FOXO1 Atrogin-1/FOXO3 Atrogin-1/FOXO1/FOXO3 Myo/MyoD/ActIIB/Samd2/NF-kB Atrogin-1/FOXO1/FOXO3/MuRF1 5 Table 7: Homeopathic RNA/DNA Dosages Dilution/Potency pg/kg 2x 50 3x 5 4x 0.5 5x 0.05 6x 0.005 III. Kits [00021 In still another aspect, the present invention provides kits for the treatment of 10 muscle wasting conditions and/or for the improvement of muscle growth and -50- WO 2008/005002 PCT/US2006/025657 i comprise a composition containing a gene-modulating oligonucleotide as described herein and instructions teaching the use of the kit according to the various methods and approaches described herein. Such kits may also include information, such as scientific literature references, package insert materials, clinical trial 5 results, and/or summaries of these and the like, which indicate or establish the activities and/or advantages of the composition. Such information may be based on the results of various studies, for example, studies using experimental animals involving in vivo models and studies based on human clinical trials. Kits described herein can be provided, marketed and/or promoted to health providers, including physicians, nurses, phannacists, 10 naturopaths, homeopaths, chiropractors, formulary officials, and the like. Kits for nutritional or homeopathic use may be provided, marketed and/or promoted directly to consumers. EXAMPLES 15 Example 1: Determination of Combined effect of Myostatin RNA Oligonucleotides in Cell Culture System Cell growth and culture C2C12 is a mouse myoblast cell line (ATCC CRL-1772), which differentiates 20 rapidly, forming contractile myotubes and producing characteristic muscle proteins. The cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) (Gibco-BRL) supplemented with 10% FCS, 1% L-glutamine, 0.5% penicillin and 0.5% streptomycin. They were incubated at 37*C under 5% C02 in a moist atmosphere. Cells approaching 50 -70% confluency were washed in phosphate buffered saline (PBS) and detached with 0.25% (w/v) Trypsin- 0.53 mM 25 EDTA solution. The detached cells were resuspended in serum-supplemented media and centrifuged at 1000 rpm at room temperature for 5 minutes. The supernatant was discarded and the cells were subcultured at a diluted cell concentration. Transfection 30 The RNA oligonucleotides were tested in cells singly and in combinations. The uptake of RNA oligonucleotides into cells was enhanced by complexing with Lipofectamine 2000. Approximately 1 x 105 C2C12 cells were seeded in 0.5 ml of growth medium without antibiotics in 24-well dishes 1 day before transfection. Cells reached approximately 50% confluency after being incubated at 37 0 C overnight. -51- WO 2008/005002 PCT/US2006/025657 Fdeath'trg1stection sample, dilute the appropriate amount of RNA was diluted oligonucleotides in 50 gl of Opti-MEM@ I Reduced Serum Medium without serum. Then one l of Lipofectamine 2000 in 50 pl of Opti-MEM@ I Medium was added. Mixed gently and incubated for 5 minutes at room temperature. After the 5-minute incubation, combined the 5 diluted RNA oligonucleotides with the diluted Lipofectamine. 2000 (total volume is 100 pl). The sample was then mixed gently and incubated for 20 minutes at room temperature to allow the RNA oligonucleotide:Lipofectamine. 2000 complexes to form. 100 pl of siRNA:Lipofectamine. 2000 complexes was added to each well (2 p.M of final concentration of RNA oligonucleotides). The cells were incubated at 37'C in a C02 10 incubator for 24-72 hours until they were ready to assay for gene knockdown. Protein analysis The cellular protein of treated and untreated C2C 12 cells was extracted for immunoblot analysis. The cells were harvested and placed on ice before being resuspended in 15 RIPA buffer (100 mM Tris-Cl, 300 mM NaCl, 0.1 %SDS, 2% NP-40, 1% sodium deoxychoate) with freshly added 100 tg/ml PMSF and 1 pg/ml aprotinin. The cell extracts were then sheared by passing through a 22-gauge needle 13 times and an extra 1 pl of PMSF was added. After standing on ice for 30-60 minutes, the cell lysate was centrifuged at 10,000 xg for 10 minutes at 4 'C. The protein-containing supernatant was collected and its concentration estimated using the 20 Biorad protein assay system (Biorad Laboratories, Richmond, CA). Protein analysis was accomplished by immunoblots also known as Western blots. Approximately 40 pg of each sample was run on a 10% SDS-PAGE gel (Invitrogen). Gel was then electrotransferred onto nitro-cellulose membrane in cold transfer buffer at 30V for an hour. The membrane was blocked with 3% BSA in TBS-T (10 mM Tris-Cl, 150 mM NaCl, 0.1 % 25 Tween-20) for 30 minutes. The membrane was then treated with Blotto A (5% skim milk powder in TBS-T) with the appropriate primary antibody (anti-myostatin and anti-MyoD) for an hour at room temperature followed by washing with TBS-T. The membrane was then probed with horseradish peroxidase conjugated secondary antibody for 45 minutes at room temperature and then washed as described above. The immunocomplexes were detected by chemiluminescence 30 reaction using reagents provided in the Amersham RCL kit (Amershan) and then exposed onto Hyperfilm (Amersham). The film was then developed to reveal protein bands. To ensure even loading, p-actin primary antibody was used to immunoblot the membrane as a control. A densitometry was performed to quantitate the intensities of each band produced from Western analysis. 35 WO 2008/005002 PCT/US2006/025657 The results showed that C2C12 cells could be efficiently transfected with RNA oligos at a efficiency of over 50%. When seven RNA oligos were screened in the cells, all showed activity at inhibition of the myostatin expression with three being most active: A (ATg Tag CgT CCg 5 AgA gAC, targeted at the 5'UTR) , B (TgC ATC ATT TTA AAA ATC AgC, targeted at the translation start site) and C (ACC TAA TgC AAA gCT CAT, targeted at the translation stop region), as assayed by western blots. All three RNA oligos are modified with 2'-Omethyl and 3' butanol blocked. 10 Example 2: Effect of single and combined RNA oligos on the muscle weight in mice This Example was designed to test the effect of antisense oligonucleotides directed to myostatin genes. 15 Materials Oligonucleotides: 3 oligonucleotides (A, B, C as in the Example 1) were straight 2'-methoxy. Sample preparation: Each oligo was dissolved in saline. For the A+B+C Group, 3 RNA oligos were mixed in equal volume. 100 ul of each mixture was used to inject mice at a dose of 5 mg/kg. 20 Experimental procedure Female mice (6-8 weeks) were housed for 7 days before injections started (Day 1). Mice were divided into five groups randomly: Group A (RNA oligo A), Group B (RNA oligo B) and Group C (RNA oligo C), Group D (RNA oligos A+B+C mixture) and Group D (saline). In each cycle of the treatment, tail vein IV injection was performed at day 1, IP injection followed at day 2 and 3. Ten treatment cycles were planned in 25 the protocol. During the experiment, the protocol was adjusted after the cycle 5 with only IV injections performed. Each day, body weight was measured before injections. At the end of the experiment, a portion of the quadriceps (rectus femoris) were dissected and weighed. Samples were divided for pathology (fixed) and molecular analysis (liquid nitrogen). Results 30 Bodyweight All mice were measured for their body weight each day, and all mice grew normally with a consistent increase of body weight. Effect of oligos on muscle weight The muscle weight was measured for each group. As shown in 35 the following table 8, compared with the saline control group, the all RNA oligo-treated group -53- WO 2008/005002 PCT/US2006/025657 sowermerease-urme muscle weight (P< 0.05), with the combined oligos being the most effective Table 8. Comparison of single and combined effect on muscle weight A B C A+B+C Increase in muscle 0.8 2.4 7.2 8.8 weight(%) III_1_1 5 This example demonstrates that treatment with modified RNA antisense oligonucleotides of the invention promotes muscle growth. Example 3: Specificity of the effect of RNA oligo on the muscle weight in mice 10 This Example was designed to test the effect of the combined antisense oligonucleotides directed to myostatin gene on muscle weight and the target gene expression. Materials Oligonucleotides: 3 oligonucleotides (A, B, C as in the Example 1) were straight 2'-methoxy. Sample preparation: 3 RNA oligos were mixed in equal volume. 100 ul of each 15 mixture was used to inject mice at a dose of 5 mg/kg. Experimental procedure Female mice (6-8 weeks) were housed for 7 days before injections started (Day 1). Mice were divided into three groups randomly: Group A (RNA oligos A+B+C), Group B (three control DNA oligos) and Group C (saline). In each cycle of the treatment, tail vein IV injection was performed at day 1, IP injection followed at day 2 and 3. 20 Ten treatment cycles were planned in the protocol. During the experiment, the protocol was adjusted after the cycle 5 with only IV injections performed. Each day, body weight was measured before injections. At the end of the experiment, a portion of the quadriceps (rectus femoris) were dissected and weighed. Samples were divided for pathology (fixed) and molecular analysis (liquid nitrogen). 25 Results Bodyweight All mice were measured for their body weight each day, and all mice grew normally with a consistent increase of body weight. 30 -54- WO 2008/005002 PCT/US2006/025657 Effedbf j6fk6d ohyiMble"eight The muscle weight was measured for each group. As shown in the following table 9, compared with the saline and DNA oligo control groups, the combined RNA oligo-treated group showed a increase in the muscle weight (P< 0.05). 5 Table 9. Specific Effect of the combined RNA oligos on muscle weight Combined RNA Control oligos Increase in muscle 11.3 -0.4 weight (%) When the muscle tissues were collected and assayed for the expression of the myostatin gene by Western blots, it was shown that the combined RNA oligos could significantly inhibit the myostatin expression, while no effect was observed for the house-keeping gene p-actin. 10 This example demonstrates that treatment with modified RNA antisense oligonucleotides of the invention could specifically inhibit the target gene expression, leading to the increase in the muscle weight. Example 4: Delivery of RNA oligos via different routes 15 This Example was designed to test the effect of the combined antisense oligonucleotides directed to myostatin gene on muscle weight by three different delivery routes. Materials Oligonucleotides: 3 oligonucleotides (A, B, C as in the Example 1) were straight 2'-methoxy. 20 Sample preparation: 3 RNA oligos were mixed in equal volume. 100 ul of each mixture was used to inject mice at a dose of 5 mg/kg. Experimental procedure Female mice (6-8 weeks) were housed for 7 days before injections started (Day 1). Mice were divided into four groups randomly: Group A (iv injection, every three days), Group B (iv and ip injection at every other days), Group C (saline, delivered 25 as in Group B) and Group D (oral). At the end of the experiment, a portion of the quadriceps (rectus femoris) were dissected and weighed. Samples were divided for pathology (fixed) and molecular analysis (liquid nitrogen). Results 30 Bodyweight All mice were measured for their body weight each day, and all mice grew normally with a consistent increase of body weight. -55- WO 2008/005002 PCT/US2006/025657 Effect of oligos on muscle weight The muscle weight was measured for each group. As shown in the following table 10, compared with the saline control group, all three delivery routes showed a increase in the muscle weight (P< 0.05). 5 Table 10. Effect of combined RNA oligos on muscle weight in three different delivery route iv iv + ip Oral Increase in muscle 25.91 22.38 18.55 weight (%) This example demonstrates that treatment with modified RNA antisense oligonucleotides of the invention could promote the muscle growth via different delivery routes. 10 Example 5: Inhibition of Foxol leads to increase in muscle weight in both normal and cancer-bearing mice. Experimental procedures 15 Animal, Oligonucleotides and Delivery Methods - BALB/c female mice (6-8 weeks old) weighing 15 to 18 g were used for normal and cancer model. Sarcoma S-180 cells in 0.2 ml of PBS (5x106 cell) were i.p. injected and grown for 7 - 10 days. Six mice per group were treated with RNA oligos via tail vein injection (100ug/0.1 ml) every two days. Mice were weighed everyday during the treatment period. Oligoribonucleotides targeted to Foxol and a control oligo were used in the 20 experiment. Mice were sacrificed at desired time points, and muscles were weighed and snap frozen in liquid nitrogen and stored at -80'C. RNA Extraction and Real-time PCR analysis - Total RNA was extracted in TRIzol (Invitrogen). RNA was separated electrophoretically on agarose gels under denaturing conditions in order to 25 confirm the integrity of ribosomal RNA bands. Single-strand cDNA synthesis was carried out from 2ug of total RNA by the reverse transcription (RT) reaction (Promega). Real-time fluorescence quantitative PCR was performed by using an Applied Biosystems Prism 7000 instrument , an Applied Biosystems SYBR@ green master mix reagent and oligonucleotide pairs to the endogenous control gene Beta-actin , MyoD, GDF-8 and foxo-1 cDNA. The reagents were 30 denatured at 950] for 10 min, followedby40 cycles of 15s at 95[ and 60 sat 600. 5'to 3'primer sequences were as follows: Beta-actin forward GAA CCC TAA GGC CAA CCG TGA A -56- WO 2008/005002 PCT/US2006/025657 BetaathAr OT AAC AGT CCG CCT AGA A MyoD forward 5' GCA AGA CCA CCA ACG CTG AT 3' MyoD reverse 5' GGT TCG GGT TGC TGG ACG TG 3' GDF-8 forward 5' CAG ACC CGT CAA GAC TCC TAC A 3' 5 GDF-8 reverse 5' CAG TGC CTG GGC TCA TGT CAA G 3' FOXO 1 forward 5' GTA CGC CGA CCT CAT CAC CA 3' FOXO1 reverse 5' TGC TGT CGC CCT TAT CCT TG 3' Average CT values for MyoD, GDF-8 and foxo 1 were calculated and normalized to CT values for -AACt Beta-actin. And the normalized values were subjected to a 2 formula to calculate the fold 10 change between the control and experiment groups. The formula and its derivations were obtained from the ABI Prism 7000 Sequence Detection System user guide. All reactions were performed in duplicates or triplicates. Western blotting - Protein was extracted from the muscle tissue of different groups with lysis 15 buffer containing 100 mM Tris-HCl, 0.05% CA-630,100ug/ml PMSF,.100ug/ml DTT,lug/ml Aprotinin and lug/ml Lenpeptin. Protein concentration of each specimen was detected by the Bradford method (Bio-Rad Laboratories). The samples were heat denatured at 95 E for 5 min, electrophoretically separated on a 12.5% SDS-PAGE, and transferred to a PVDF membrane. The membrane was blocked with 5% non-fat dry milk in TBST buffer(50 mM Tris-HCl, 100 mM 20 NaCl, and 0.1% Tween-20, pH 7.4) and incubated with monoclonal anti-MyoD diluted at 1/200 (BD, Pharmingen) , monoclonal anti-Myostatin diluted at 1/100( Santa Cruz Biotechnology ) and anti-beta actin diluted at 1/250( Santa Cruz Biotechnology), and further incubated for 90 min at 37 0.Bound antibodies were visualized by subsequent chemiluminescent reaction with a horseradish peroxidase conjugated IgG(1:3000) in the ECL system (Amersham). 25 The image and data were analyzed with bandscan 5.0 software. Statistical analysis - Data were expressed as means L SD and subjected to one-way AVONA with factors of treatment, genotype or wild type. Comparisons between two groups were performed by unpaired Student's t test. A value of p < 0.05 was considered significantly different.. 30 Results 1. Foxo 1 RNA oligonucleotide promoted muscle growth in normal mice -57- WO 2008/005002 PCT/US2006/025657 Ihordbftd"anite the-effets of the Foxol RNA oligo on the muscle growth, the leg muscles were collected and weighed at the end of the treatment. The results showed that the mass of muscles of normal mice was increased by 10% while no significant change was observed in the control groups (Figure 1). When the muscle tissues were analyzed for the expression of the target 5 gene, it was shown that the protein levels of GDF-8 decreased by 48.5% and the MyoD increased by 42% compared to control group (Fig. 2). At the RNA level as measured by Real Time PCR, the mRNA levels of Foxol decreased by 75%, GDF-8 decreased by 49% MyoD increased by 58% compared to control group (Fig. 2). This result clearly demonstrated that the Foxol RNA oligo could increase the muscle growth by direct inhibition of the Foxol expression and indirect impact 10 on the myostatin and MyoD expression. 2. Increase muscle weight in cancer cachexia model by Foxol RNA oligonucleotide To test the RNA oligo effect on muscle mass in a relevant disease model, an ascetic tumor S180 15 was used as a cancer cachexia model where the muscle loss is a characteristic. As for in the normal mice, the group injected with Foxol RNA oligo showed a muscle mass increased by 32.8% compared to control group (Fig 3). At protein level, myostatin decreased by 40.4%, MyoD increased by 41.8% (Fig.4). At mRNA level, foxol expression decreased by 81%, myostatin decreased by 58%, MyoD increased by 66% compared to control group (Fig.4). This result 20 demonstrated that the use of Foxo1 oligo could impact on the muscle growth in cancer cachexia model. Example 6: Inhibition of Myostatin gene expression by RNA oligos increased muscle growth in tumor-bearing mice 25 Experimental procedures Animal, Oligonucleotides and Delivery Methods - BALB/c female mice (6-8 weeks old) weighing 15 to 18 g were used for cancer model. Sarcoma S-180 cells in 0.2 ml of PBS (5x10 6 cell) were i.p. injected and grown for 7 - 10 days. Six mice per group were treated with RNA oligos via tail 30 vein injection (100ug/0.1 ml) every two days. Mice were weighed everyday during the treatment period. Oligonucleotides targeted to Myostatin and a control oligo were used in the experiment. Mice were scarified at desired time points, and leg muscles including the quadriceps (rectus femoris), the gastrocnemius, triceps, and the EDL were weighed and snap-frozen in liquid nitrogen and stored at -80'C. -58- WO 2008/005002 PCT/US2006/025657 Statistical analysis - Data were expressed as means ± SD and subjected to one-way AVONA with factors of treatment, genotype or wild type. Comparisons between two groups were performed by unpaired Student's t test. A value of p < 0.05 was considered significantly different.. 5 Quantitative RT-PCR analysis of mRNA -Total RNA was isolated from cells using RNA preparation kits from TRIZOL@ reagent (Invitrogen). cDNA was generated using InpromII@ reverse transcriptase (Promega) and oligo(d)T primers, according to the manufacturers instructions, typically using 1 pg of total RNA per reaction. Quantitative PCR was performed 10 using an Applied Biosystems Prism 7000 instrument using Applied Biosystems SYBR@ green master mix reagent and oligonucleotide pairs to human cell house-keeping gene beta-actin cDNA. 5' to 3' primer sequences were as follows: Beta-actin forward GAA CCC TAA GGC CAA CCG TGA A, Beta-actin reverse CTC AGT AAC AGT CCG CCT AGA A, GDF-8 forward CAg ACC CgT CAA gAC TCC TAC A and GDF-8 reverse CAg TgC CTg ggC TCA 15 TgT CAA g, MyoD forward gCA AgA CCA CCA ACg CTg AT and MyoD reverse ggT TCg ggT TgC Tgg ACg Tg. Average CT values for MyoD and GDF-8 were calculated and normalized to CT values for Beta-actin. The average Ct value from each three experiments was calculated, and the results were graphed with the corresponding standard deviation indicated with error bars in the figures. The formula and its derivations were obtained from the ABI Prism 20 7000 Sequence Detection System user guide. Statistical analysis- Data were expressed as means ± SD and subjected to one-way AVONA with factors of treatment, genotype or wild type. Comparisons between two groups were performed by unpaired Student's t test. A value of p < 0.05 was considered significantly different. 25 Results RNA oligos targeted to myostatin gene decreased myostatin expression and increased the mass of muscles in S-180 implanted mice The three RNA oligos targeted at the Myostatin gene were mixed in an equal mole and the mixture was used in the experiment. The effect on 30 muscle mass in S-180 implanted mice was tested in S-180 implanted mice. The results showed that the muscle mass in the group treated with the RNA oligo mixture increased by 26% compared to control group (Figure 5 A, p<0.05). As in Figure 5B, the ratio of skeletal muscle mass and body mass in the group injected RNA oligos increased by 10.4% (p<0.05). At mRNA -59- WO 2008/005002 PCT/US2006/025657 lvlVhybd1iltfri deerded'by 21.3% (Fig. 5 C, p<0.01), MyoD increased by 1.23-fold compared to control group (Fig.5 D, p<0.01). While preferred embodiments of the present invention have been shown and described herein, it 5 will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and 10 structures within the scope of these claims and their equivalents be covered thereby. -60-

Claims (17)

1. A composition suitable for administration to an animal comprising a modified oligonucleotide containing 7 to 75 contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages, wherein the modified oligonucleotide is complementary to 5 a region of a gene selected from the group consisting of the 5'UTR region, translational start site, the 3' UTR, and translational termination site, and wherein the gene codes for a gene product involved in a muscle wasting condition.

2. The composition of claim 1 wherein the modified oligonucleotide has a Tm of about 10 75-115 *C. at a concentration of 1 mM and a length of 10 to 26 bases, or a Tm of about 40 0 C to 85 *C at a concentration of 1 pM and a length of 10 to 26 bases.

3. The composition of claim 1 wherein the oligonucleotide comprises a nucleotide selected from the group consisting of ribonucleotides and deoxyribonucleotides. 15

4. The composition of claim 1 wherein oligonucleotides comprise one or more nucleotides in which the 2' position comprises a substituent.

5. The composition of claim 4 wherein the 2' substituent is selected from the group 20 consisting of hydrogen, methoxy, propoxy, methoxy-ethoxy, fluorine, chlorine, bromine and iodine.

6. The composition of claim 1 wherein the modified oligonucleotide is 3' and/or 5' end-modified. 25

7. The composition of claim 1 wherein the modified oligonucleotide is 3' and/or 5' end-blocked.

8. The composition of claim 1 wherein the oligonucleotide is an antisense 30 oligonucleotide.

9. The composition of claim 8 wherein the antisense oligonucleotide is complementary to a myostatin gene -61- WO 2008/005002 PCT/US2006/025657 '1(: The domposi'tidh of claim 9 wherein the myostatin gene is an animal myostatin gene.

11. The composition of claim 9 wherein the myostatin gene is a mammalian myostatin 5 gene.

12. The composition of claim 9 wherein the myostatin gene is a human myostatin gene.

13. The composition of claim 8 wherein the oligonucleotide comprises a sequence 10 selected from the group consisting of SEQ ID NOS 1-191.

14. The composition of claim 1 wherein the oligonucleotide comprises an RNAi, ribozyme or deoxyribozyme. 15 15. The composition of claims 1 further comprising a plurality of modified oligonucleotides.

16. The composition of claim 15 comprising two modified oligonucleotides. 20 17. A method of treating a muscle wasting condition comprising administering to an individual suffering from a muscle wasting condition an effective amount of the composition of claim 1.

18. A method of promoting muscle growth in an individual comprising administering to 25 the individual an effective amount of the composition of claim 1.

19. The method of claim 17 or 18 wherein the individual is a mammal.

20. The method of claim 17 or 18 wherein the individual is a human. 30 -62-